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ABSTRACT 
The skin protects the organism from the environment and shields it from the constant danger 
of infections by microorganisms. Keratinocytes are epithelial cells in the skin that constitute a 
physical barrier towards the environment. More than that, they are essential players in innate 
immunity: Keratinocytes can recognize invading pathogens by a variety of receptors, among 
them Toll-like receptors (TLRs). Activation of keratinocytes by pathogenic triggers leads to 
the induction of an inflammatory reaction in the skin, finally leading to the destruction and 
elimination of the pathogens. After clearance of the infection, homeostasis needs to be 
restored in order to avoid pathophysiological chronic inflammation.  
Psoriasis is a common chronic inflammatory skin disease characterized by local and systemic 
activation of both the innate and the adaptive immune system. In psoriasis skin lesions, 
hyperproliferation and activation of keratinocytes is combined with a massive infiltration of 
immune cells into the skin.  
MicroRNAs are endogenous short RNA molecules that regulate gene expression at the post-
transcriptional level. They have been shown to be involved in the regulation of all basic 
biological processes. The aim of this thesis was to study the role of microRNAs in skin 
immunity, with a focus on their regulation and function in keratinocytes under homeostatic 
and inflammatory conditions.  
 
We have characterized systematically the microRNA expression profile of keratinocytes 
treated with ligands for TLR2, TLR5 and TLR3, showing that a distinct subset of 
microRNAs is regulated by different TLR ligands (Paper I). MiR-146a was strongly induced 
by all studied TLR ligands, while other microRNAs were regulated in a TLR- or time point-
specific manner. A detailed analysis of the regulation of miR-146a in keratinocytes revealed 
its long-lasting induction upon TLR2 stimulation, leading to a global repression of the 
inflammatory response (Paper II). Functionally, miR-146a acts as a negative feedback to 
counteract TLR2-induced inflammation and to restore tissue homeostasis by suppressing the 
production of inflammatory mediators and the chemotactic attraction of immune cells. 
Moreover, endogenous miR-146a was essential to prevent unstimulated keratinocytes from 
producing inflammatory mediators, thus protecting from unwanted inflammation in the 
absence of a trigger. In the chronically inflamed skin of psoriasis patients, miR-146a was 
overexpressed and keratinocytes were partially responsible for this phenotype (Paper III). 
Pro-inflammatory cytokines of the IL-1 family were shown to be strong inducers of miR-
146a, plausibly responsible for the miR-146a overexpression in psoriasis keratinocytes. 
Taken together, these results propose that miR-146a regulates skin immune responses after 
infection or skin injury and may set the threshold of activation in keratinocytes.  
We have identified miR-31 as another microRNA overexpressed in psoriasis keratinocytes 
and regulating the keratinocyte immune responses (Paper IV). MiR-31 could be induced by 
TGF-β1 in vitro and in vivo. Inhibition of endogenous miR-31 decreased the inflammatory 
activity of keratinocytes, suggesting that miR-31 acts as a pro-inflammatory microRNA and 
contributes to the chronic inflammation in psoriasis lesions.  
In conclusion, the data presented in this thesis underline the crucial importance of 
microRNAs in the innate immune response of keratinocytes. The modulation of the local 
inflammatory environment by microRNAs may explain more of the unknown underlying 
factors regulating susceptibility to autoimmune diseases such as psoriasis.   
  
  
LIST OF PUBLICATIONS  
I. Activation of Toll-like receptors alters the microRNA expression profile 
of keratinocytes  
Florian Meisgen*, Ning Xu Landén*, Charbel Bouez, Michela Zuccolo, 
Audrey Gueniche, Mona Ståhle, Enikö Sonkoly, Lionel Breton and Andor 
Pivarcsi  
* equal contribution  
Experimental Dermatology. 2014 Apr;23(4):281-3  
 
II. MiR-146a negatively regulates TLR2-induced inflammatory responses in 
keratinocytes  
Florian Meisgen, Ning Xu Landén, Aoxue Wang, Bence Réthi, Charbel 
Bouez, Michela Zuccolo, Audrey Gueniche, Mona Ståhle, Enikö Sonkoly, 
Lionel Breton and Andor Pivarcsi  
Journal of Investigative Dermatology. 2014 Jul;134(7):1931-40  
 
III. MiR-146a is up-regulated in psoriasis and acts as a negative feedback on 
IL-36 and IL-1β signaling in keratinocytes  
Florian Meisgen, Ankit Srivastava, Ning Xu Landén, Mona Ståhle, Andor 
Pivarcsi and Enikö Sonkoly  
Manuscript  
 
IV. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory 
cytokine and chemokine production in keratinocytes via targeting 
serine/threonine kinase 40  
Ning Xu, Florian Meisgen, Lynn Butler, Gangwen Han, Xiao-Jing Wang, 
Cecilia Söderberg-Nauclér, Mona Ståhle, Andor Pivarcsi and Enikö Sonkoly  
The Journal of Immunology. 2013 Jan 15;190(2):678-88  
 
 
  
PUBLICATIONS NOT INCLUDED IN THIS THESIS  
MiR-155 is overexpressed in patients with atopic dermatitis and modulates 
T-cell proliferative responses by targeting cytotoxic T lymphocyte-
associated antigen 4 
Enikö Sonkoly, Peter Janson, Marja-Leena Majuri, Terhi Savinko, Nanna 
Fyhrquist, Liv Eidsmo, Ning Xu, Florian Meisgen, Tianling Wei, Maria Bradley, 
Jan Stenvang, Sakari Kauppinen, Harri Alenius, Antti Lauerma, Bernhard 
Homey, Ola Winqvist, Mona Ståhle and Andor Pivarcsi  
Journal of Allergy and Clinical Immunology. 2010 Sep;126(3):581-9.e1-20  
 
MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte 
proliferation by targeting FGFR2 
Ning Xu, Petter Brodin, Tianling Wei, Florian Meisgen, Liv Eidsmo, Nikoletta 
Nagy, Lajos Kemeny, Mona Ståhle, Enikö Sonkoly and Andor Pivarcsi  
Journal of Investigative Dermatology. 2011 Jul;131(7):1521-9  
 
MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma  
Enikö Sonkoly, Jacob Lovén, Ning Xu, Florian Meisgen, Tianling Wei, Petter 
Brodin, Viljar Jaks, Maria Kasper, Takashi Shimokawa, Masako Harada, Johan 
Heilborn, Mari-Anne Hedblad, Andreas Hippe, Dan Grandér, Bernhard Homey, 
Peter Zaphiropoulos, Marie Arsenian-Henriksson, Mona Ståhle and Andor 
Pivarcsi 
Oncogenesis. 2012 Mar 12;1:e3  
 
MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis 
Florian Meisgen, Ning Xu, Tianling Wei, Peter Janson, Susanna Obad, Oliver 
Broom, Nikoletta Nagy, Sakari Kauppinen, Lajos Kemény, Mona Ståhle, Andor 
Pivarcsi and Enikö Sonkoly  
Experimental Dermatology. 2012 Apr;21(4):312-4  
 
MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits 
cutaneous squamous cell carcinoma cell proliferation, migration, and 
invasion  
Ning Xu, Lingyun Zhang, Florian Meisgen, Masako Harada, Johan Heilborn, 
Bernhard Homey, Dan Grandér, Mona Ståhle, Enikö Sonkoly and Andor 
Pivarcsi  
The Journal of Biological Chemistry. 2012 Aug 24;287(35):29899-908   
 
Changes in the level of serum microRNAs in patients with psoriasis after 
antitumour necrosis factor-α therapy  
Andor Pivarcsi, Florian Meisgen, Ning Xu, Mona Ståhle and Enikö Sonkoly  
British Journal of Dermatology. 2013 Sep;169(3):563-70   
 
Interleukin-8 is regulated by miR-203 at the posttranscriptional level in 
primary human keratinocytes  
Tianling Wei, Ning Xu, Florian Meisgen, Mona Ståhle, Enikö Sonkoly and 
Andor Pivarcsi  
European Journal of Dermatology. 2013 Apr 19  
 
  
  
MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and 
regulates cell motility and colony formation ability of tumor cells  
Aoxue Wang, Ning Xu Landén, Florian Meisgen, Warangkana Lohcharoenkal, 
Mona Ståhle, Enikö Sonkoly and Andor Pivarcsi  
PLoS One. 2014 Jul 28;9(7):e103206  
 
MicroRNA-132 supports wound healing by enhancing the transition from 
inflammation to proliferation  
Dongqing Li, Aoxue Wang, Xi Liu, Florian Meisgen, Jacob Grünler, Ileana 
Botusan, Sampath Narayanan, Erdem Erikci, Lei Du, Andor Pivarcsi, Enikö 
Sonkoly, Kamal Chowdhury, Sergiu-Bogdan Catrina, Mona Ståhle and Ning Xu 
Landén 
Submitted  
 
MicroRNA-31 promotes skin wound healing by enhancing keratinocyte 
proliferation and migration   
Dongqing Li, Aoxue Wang, Florian Meisgen, Andor Pivarcsi, Enikö Sonkoly, 
Mona Ståhle and Ning Xu Landén 
Submitted  
 
 
CONTENTS 
1 Background ..................................................................................................................... 1 
1.1 The Skin ................................................................................................................. 1 
1.1.1 The skin as an immune organ ................................................................... 2 
1.1.2 The skin microbiome ................................................................................ 4 
1.2 Innate Immunity .................................................................................................... 6 
1.2.1 Toll-like receptors ..................................................................................... 6 
1.2.2 TLR signaling ............................................................................................ 7 
1.2.3 NF-κB ........................................................................................................ 9 
1.2.4 Cytokines ................................................................................................. 10 
1.2.5 Chemokines ............................................................................................. 13 
1.2.6 Antimicrobial peptides ............................................................................ 15 
1.3 Psoriasis ............................................................................................................... 17 
1.3.1 The genetic background of psoriasis ...................................................... 18 
1.3.2 The pathogenesis of psoriasis ................................................................. 19 
1.4 Non-coding RNAs ............................................................................................... 23 
1.4.1 microRNAs.............................................................................................. 24 
1.4.2 microRNAs in diseases ........................................................................... 26 
1.4.3 microRNAs in psoriasis .......................................................................... 27 
2 Aims ............................................................................................................................... 29 
3 Materials and Methods .................................................................................................. 31 
4 Results and Discussion .................................................................................................. 37 
4.1 Identification of microRNAs involved in the innate immune function of 
keratinocytes ........................................................................................................ 37 
4.2 The regulation of miR-146a by TLR2 ligands in keratinocytes ........................ 40 
4.2.1 The kinetics of miR-146a induction by TLR signaling ......................... 40 
4.2.2 Induction of miR-146a upon TLR2 stimulation is mediated 
through the NF-κB and MAPK pathways .............................................. 41 
4.3 miR-146a in psoriasis .......................................................................................... 43 
4.3.1 miR-146a is up-regulated in psoriasis keratinocytes ............................. 43 
4.3.2 Induction of miR-146a by psoriasis-relevant cytokines ........................ 44 
4.3.3 IL-36- and IL-1-dependent induction of miR-146a ............................... 46 
4.4 The function of miR-146a in keratinocytes ........................................................ 48 
4.4.1 miR-146a suppresses the expression of inflammatory mediators ......... 48 
4.4.2 miR-146a has a global impact on the transcriptome of 
keratinocytes ............................................................................................ 49 
4.4.3 miR-146a regulates the NF-κB pathway ................................................ 50 
4.4.4 miR-146a targets IRAK1 and TRAF6.................................................... 51 
4.4.5 miR-146a modulates the communication of keratinocytes with the 
local environment .................................................................................... 51 
  
  
4.5 miR-146a – a gatekeeper of immunity in skin ................................................... 54 
4.6 miR-31 in psoriasis .............................................................................................. 58 
4.7 The function of miR-31 in keratinocytes ............................................................ 59 
4.7.1 miR-31 regulates inflammatory mediators ............................................. 59 
4.7.2 miR-31 targets STK40 ............................................................................ 60 
4.8 miR-31 – a pro-inflammatory miRNA ............................................................... 61 
5 Conclusion ..................................................................................................................... 64 
6 Acknowledgements ....................................................................................................... 67 
7 References ..................................................................................................................... 71 
 
  
LIST OF ABBREVIATIONS 
3'-UTR Three prime untranslated region 
AMP  Antimicrobial peptide 
AP-1  Activator protein 1 
BCL-3 B-cell lymphoma 3-encoded protein 
CARD14 Caspase recruitment domain family, member 14 
CCL  CC chemokine ligand  
CCR  CC chemokine receptor  
CXCL  CXC chemokine ligand  
CXCR CXC chemokine receptor 
DC Dendritic cell 
DEPC  Diethylpyrocarbonate 
DGCR8 DiGeorge Syndrome Critical Region Gene 8  
EGF Epidermal growth factor  
ELISA  Enzyme-linked immunosorbent assay 
Elk-1  E26 transformation-specific domain-containing protein 1 
ERK Extracellular-signal-regulated kinase  
FFPE Formalin-Fixed, Paraffin-Embedded 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GWAS Genome-wide association study 
hBD-2  Human beta-defensin 2 
HUVEC  Human umbilical vein endothelial cells 
ICAM-1 Intercellular adhesion molecule 1 
IFN-α Interferon alpha  
IFN-γ  Interferon gamma 
IKK IκB-kinase  
IL  Interleukin  
IL-1R Interleukin 1 receptor, type I 
IL-1ra Interleukin 1 receptor antagonist  
IL-1RAcP Interleukin 1 receptor accessory protein 
IL-1Rrp2 Interleukin 1 receptor-like 2 
IL-36ra  Interleukin 36 receptor antagonist  
IRAK  Interleukin-1 receptor-associated kinase  
  
IRF  Interferon regulatory factor  
IκB Inhibitor of NF-κB  
JNK  c-Jun N-terminal kinases 
KGF Keratinocyte growth factor 
LFA-1 Lymphocyte function-associated antigen 1 
LPS Lipopolysaccharides 
MAL MyD88-adapter-like protein  
MAPK  Mitogen-activated protein kinase  
mDC Myeloid dendritic cell 
MEK1/2  MAPK/ERK kinase 1/2 
miRNA  microRNA 
MyD88 Myeloid differentiation primary response gene (88) 
NEMO NF-κB essential modulator 
NFKBIA NF-κB inhibitor, alpha 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIK NF-κB inducing kinase 
NK cell Natural killer cell 
p38  p38 mitogen-activated protein kinase 
PAMP  Pathogen-associated molecular pattern  
PBMC Peripheral blood mononucleated cell 
pDC Plasmacytoid dendritic cell 
PKC  Protein kinase C  
pri-miR Primary microRNA 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RISC RNA-induced silencing complex 
RNAi RNA interference  
SALT Skin-associated lymphoid tissue 
SCID  Severe combined immunodeficiency  
siRNA Small interfering RNA 
SMAD Homolog of small body size and mothers against 
decapentaplegic  
SNP single nucleotide polymorphism  
SOCS-3 Suppressor of cytokine signaling 3 
STK40  Serine/threonine-protein kinase 40 
TAB TAK1-binding protein  
TAK Transforming-growth-factor-beta-activated kinase 
TGF-β Transforming growth factor beta 
TH cell T helper cell 
TIR Toll/Interleukin-1 receptor  
TIRAP Toll-interleukin 1 receptor domain containing adaptor protein 
TLR  Toll-like receptor 
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 
TNF-α  Tumor necrosis factor alpha 
TNIP TNFAIP3 interacting protein 3 
TPA 12-O-Tetradecanoylphorbol-13-acetate 
TRAF3IP2 TRAF3 interacting protein 2 
TRAF6  TNF receptor-associated factor 6 
TRAM TRIF-related adaptor molecule 
TRIF TIR-domain-containing adapter-inducing interferon-beta 
VCAM-1  Vascular cell adhesion molecule 1 
VLA-1 Very late activation antigen 1 
 
  1 
1 BACKGROUND  
Multicellular organisms have developed highly sophisticated mechanisms during evolution to 
protect themselves from the permanent attack of pathogens in the environment. Constant 
surveillance of the tissues, specific recognition of potentially dangerous invaders and the 
elicitation of a pathogen-specific immune response are key steps for a successful immune 
defense. Inflammatory reactions are beneficial not only to protect from infections but also 
from malignancies; without inflammatory mechanisms no complex organism would be 
viable. However, an overreaction or lack of termination of the immune response may 
eventually lead to chronic inflammation or autoimmunity; therefore a precise control of the 
immune response balancing pro- and anti-inflammatory factors is a necessity for survival and 
health.  
 
1.1 THE SKIN  
The skin forms a physical, chemical and immunological barrier of the organism towards the 
environment, preventing the invasion of pathogens, protecting from trans-epithelial water loss 
and regulating body temperature. Human skin consists of three major layers, the epidermis, 
the dermis and the underlying subcutaneous fat tissue (Figure 1).  
Figure 1: Structure of the skin (left) and the epidermis (right). Illustration from the National Cancer Institute 
and the Wikiversity Journal of Medicine.  
 
The epidermis consists mainly of keratinocytes which create the outermost barrier of the skin 
in a structure of multiple layers (Figure 1). From bottom to top, these histologically distinct 
 2 
epidermal layers are termed stratum basale, stratum spinosum, stratum granulosum, stratum 
lucidum and stratum corneum. Keratinocytes in the stratum basale proliferate constantly and 
migrate upwards, thus forming the different epidermal layers. During this process, the 
keratinocytes differentiate in various stages until they finally die and shed off. Keratinocytes 
are thus forming the physical barrier of the skin, but more than that they are also important 
players in the immune surveillance of the skin by actively recognizing invading pathogens 
(Gutowska-Owsiak and Ogg, 2012).  
Besides keratinocytes, the epidermis also contains Langerhans cells, which are epidermis-
specific antigen-presenting dendritic cells that capture and present foreign antigens towards 
cells of the adaptive immune system (Romani et al., 2012). The basal layer of the epidermis 
also contains a population of melanocytes that produce melanin, a pigment that protects the 
organism from damages by UV irradiation (Brenner and Hearing, 2008), as well as Merkel 
cells, which sense tactile sensation (Halata et al., 2003).  
Below the epidermis is the dermis, which is characterized by collagen- and elastin-rich 
connective tissue. The extensive extracellular matrix in the dermis creates stability and 
flexibility of the skin and is majorly produced by fibroblasts. The dermis contains blood 
vessels, hair follicles, sweat glands and sebaceous glands. The hair follicle does not only 
produce hair, but serves also as a niche for epidermal stem cells (Blanpain and Fuchs, 2006). 
The dermis hosts a large number and variety of immune cells, among them macrophages, 
myeloid dendritic cells, plasmacytoid dendritic cells, T cells, B cells and NK cells, which 
altogether provide additional immune surveillance, memory of previous infections and a 
quick primary immune response against invading pathogens. It has been estimated that skin 
resident T cells outnumber T cells in the circulation by two to one (Clark et al., 2006), 
highlighting the importance of immune cells within the skin.  
Under the dermis, a layer of subcutaneous fat and connective tissue in varying thickness 
creates the third layer of the skin.  
 
1.1.1 The skin as an immune organ  
The skin can be regarded as a specialized lymphoid organ, sometimes referred to as SALT 
(skin-associated lymphoid tissue) (Streilein, 1983). According to this concept, different cells 
in the skin can recognize invading pathogens by the repertoire of the innate and adaptive 
immune system and induce a protective immune response.  
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The cells in the epidermis are important players in the immune surveillance of the skin. Due 
to their close proximity towards the environment they are the first cells encountering invading 
pathogens. Keratinocytes recognize conserved motifs of invading pathogens via Toll-like 
receptors (TLRs; chapter 1.2.1), thus being key players of the innate immune system 
(Pivarcsi et al., 2004; Miller, 2008). Keratinocyte activation by TLR stimulation, but also by 
other external stimuli, such as physical trauma or UV irradiation, induces the production of 
numerous cytokines, chemokines and antimicrobial peptides (chapter 1.2.4 - 1.2.6). These 
keratinocyte-derived inflammatory mediators serve as alarm signals for the innate and 
adaptive immune system, regulate the recruitment, activation and retention of immune cells 
(neutrophils, granulocytes, dendritic cell precursors and T cells) to the skin and modulate 
their function (Goodarzi et al., 2007; Nestle et al., 2009a) (Figure 2).  
 
 
Figure 2: The immune functions of keratinocytes in the skin upon invasion of pathogens. Illustration by Andor 
Pivarcsi.   
Immune cells can enter the skin by extravasation from the circulation. In a highly 
orchestrated cascade, leukocytes bind towards the endothelial cell wall of the blood vessel, 
using selectins and integrins as adhesion points (Ley et al., 2007). After initial rolling along 
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the vessel wall, the leukocytes become activated by chemokines. Leukocyte integrins (e.g. 
LFA-1, VLA-4) bind to endothelial immunoglobulin molecules (e.g. ICAM-1, VCAM-1), 
leading to the arrest of the cell at a specific site. The leukocytes then start to transmigrate 
between the endothelial cells into the tissue (Nourshargh et al., 2010). The precise 
coordination of time, tissue site and intensity of the recruitment of specific immune cells is 
required to maintain the balance between inflammation and tissue homeostasis (Li et al., 
2008).  
Langerhans cells act as antigen-presenting cells in the epidermis. They provide immune 
surveillance in the epidermis by phagocytic uptake of foreign material within the skin 
followed by antigen processing and presentation to cells of the adaptive immune system. This 
leads eventually to the activation of antigen-specific skin-homing T cells and a general 
attraction of immune cells into the skin (Romani et al., 2012). But also immune-suppressive 
functions of Langerhans cells have been discussed, potentially being responsible for the 
tolerance towards commensal bacteria on the skin (van der Aar et al., 2007).  
Cross-talk between keratinocytes, stromal cells and immune cells is of crucial importance for 
regulating physiological inflammatory reactions and homeostasis in the skin (Lowes et al., 
2014). An appropriate immune response of the skin towards local infections or wounds 
requires an orchestrated action of all cell types in the skin, involving pro-inflammatory 
cytokines and chemokines. Equally important are mechanisms to restore homeostasis after 
clearance of the infection. Resolution of inflammation is necessary to avoid tissue 
destruction, again involving all cells present. Failure of any cell type to terminate the 
inflammatory response may lead to the re-activation of other cells in the skin and thus start a 
vicious cycle of chronic inflammation. Therefore the communication of the different cell 
types in the skin with each other is a key factor in maintaining homeostasis. It is also highly 
relevant during the development of chronic inflammatory skin diseases such as psoriasis.  
 
1.1.2 The skin microbiome  
The skin is not sterile, instead it is inhabited by a large number of microorganisms, including 
bacteria, fungi, viruses and also mites (Grice and Segre, 2011). The composition of the skin 
microbiome is diverse and varies dependent on host and environmental factors. Host factors 
such as body site, sex and age but also genetic variances influence the skin microbiome 
largely. It is therefore individual and has recently even been shown to influence the microbial 
  5 
composition of the environment (Lax et al., 2014). The colonization of the skin with non-
pathogenic commensal microbes appears to prevent the establishment and overgrowth of 
potentially pathogenic microbes, thus protecting the organism from infection (Sanford and 
Gallo, 2013). The skin on the other hand has during the co-evolution with microbes acquired 
the ability to tolerate commensals, but actively fight pathogens, by that maintaining the 
balance between homeostasis and inflammation. To distinguish between commensals and 
pathogens is therefore of major importance for preserving the integrity of the skin. 
Interestingly, TLR2 ligands prepared from commensals can have an immune-suppressive 
function on keratinocytes, compared to pro-inflammatory effects of TLR2 ligands prepared 
from pathogenic bacteria (Lai et al., 2009). These observations suggest that there are defined 
mechanisms and structures helping the immune system to differentiate between commensals 
and pathogens.   
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1.2 INNATE IMMUNITY  
1.2.1 Toll-like receptors  
Toll-like receptors (TLRs) recognize evolutionary conserved motifs of pathogens, so called 
pathogen-associated molecular patterns (PAMPs) (Kumar et al., 2011). In humans, 10 TLRs 
are known (TLR1 - TLR10), each having a specific class of binding ligands (Figure 3).  
TLR1, TLR2, TLR4, TLR5 and TLR6 are primarily expressed on the cell surface and they 
recognize PAMPs derived from bacteria, fungi or protozoae (Kawai and Akira, 2010). TLR2 
recognizes various lipopeptides derived from the cell wall of Gram-positive bacteria or fungi. 
TLR2 can recognize among others bacterial peptidoglycans and lipoteichoic acid 
(Schwandner et al., 1999), bacterial lipoarabinomannan (Underhill et al., 1999) and yeast-
derived zymosan (Ozinsky et al., 2000). It can form heterodimers with TLR1 or TLR6, 
specifically differentiating between tri-acetylated (TLR2-TLR1) and di-acetylated (TLR2-
TLR6) lipopeptides (Takeuchi et al., 2001; Takeuchi et al., 2002). TLR4 recognizes 
lipopolysaccharides (LPS, also termed endotoxin), a major component of the cell wall of 
Gram-negative bacteria (Poltorak et al., 1998). TLR5 recognizes flagellin, an evolutionary 
conserved globular protein in the flagella of bacteria, thus enabling the detection of 
flagellated bacteria (Hayashi et al., 2001).  
TLR3, TLR7, TLR8 and TLR9 are located in the endosomal compartments of the cell and 
recognize mainly viral and bacterial nucleic acids. TLR3 recognizes double-stranded RNA 
which is usually produced by RNA viruses, and is absent in mammalian cells (Alexopoulou 
et al., 2001). Of note, also certain siRNAs have been shown to trigger the stimulation of 
TLR3, raising concerns about the safety and side-effects of RNAi-based drugs (Kleinman et 
al., 2008). TLR7 and TLR8 recognize single-stranded RNA, mostly of viral origin (Diebold 
et al., 2004; Heil et al., 2004). Interestingly, microRNAs secreted by cancer cells have been 
shown to activate TLR8 signaling in immune cells, implicating that TLR signaling can also 
be triggered by non-pathogenic motifs and have a function in the communication between 
tumor cells and the immune system (Fabbri et al., 2012). TLR9 is specialized to recognize 
unmethylated CpG motifs in DNA, which occur in bacterial and viral DNA, but are very rare 
in mammalian cells (Bauer et al., 2001).  
No ligand is known so far for TLR10, but it has been suggested that TLR10 has a modulatory 
function by inhibiting the TLR2-dependent activation of peripheral blood mononuclear cells 
(PBMCs) (Oosting et al., 2014).  
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Human keratinocytes express several of the mentioned TLRs. There is consensus that TLR1, 
TLR2, TLR3 and TLR5 are expressed by human keratinocytes, while TLR7 and TLR8 are 
absent (Baker et al., 2003; Mempel et al., 2003; Kollisch et al., 2005; Lebre et al., 2007). The 
expression of TLR4, TLR6, TLR9 and TLR10 though is controversial; their presence on 
keratinocytes is seen in some of these studies, but not in others.  
 
1.2.2 TLR signaling  
Recognition of the regarding ligand by TLRs leads to an intracellular signaling cascade that 
induces an appropriate inflammatory response of the cell. In principal, two major signaling 
pathways can be distinguished, the MyD88-dependent production of pro-inflammatory 
cytokines and chemokines, and the TRIF-dependent expression of anti-viral interferons 
(Kawasaki and Kawai, 2014) (Figure 3).  
All TLRs have an intracellular Toll/IL-1 receptor (TIR) domain that can also be found on 
IL-1 receptors (Slack et al., 2000). Binding of the regarding ligand induces the dimerization 
of TLRs, which leads to the intracellular recruitment of adaptor molecules to the TIR domain. 
Four adaptor molecules are known, MyD88, TRIF, TRAM and TIRAP/MAL. All TLRs 
except TLR3 recruit MyD88 upon activation. TIRAP/MAL is a sorting adaptor that recruits 
MyD88 towards the activated TLR (Fitzgerald et al., 2001; Yamamoto et al., 2002; Kagan 
and Medzhitov, 2006). Kinases of the IRAK family subsequently connect with MyD88 and 
the following phosphorylation cascades lead to the activation of IRAK4 and IRAK1 (Li et al., 
2002). In this submembraneous signaling complex, the ubiquitin ligase TRAF6 is recruited 
and activated by self-polyubiquitination (Cao et al., 1996; Deng et al., 2000). TRAF6 binds 
then to TAK1, TAB1, TAB2 and TAB3, and in conjunction this signaling complex activates 
the NF-κB pathway by ubiquitination of NEMO (IKKγ) and phosphorylation of IKKβ 
(Ninomiya-Tsuji et al., 1999; Ajibade et al., 2013). The activated IKK complex then degrades 
IκB, which leads to the release of NF-κB (chapter 1.2.3).  
In addition to NF-κB, the TRAF6 / TAK1 signaling complex also activates MAPK pathways 
by phosphorylation, among them JNK, ERK1/2 and p38 (Kawasaki and Kawai, 2014). 
MAPKs are a large group of serine/threonine kinases that transduce a variety of cellular 
signals, including mitogenic (growth stimulating) and inflammatory signals (Cargnello and 
Roux, 2011). They mediate the activation of transcription factors (e.g. AP-1, Elk-1, PKC, 
p53), thus modulating the cellular activity. This transcriptional regulation influences for 
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example proliferation, differentiation, immune responses and apoptosis. The MAPK 
pathways overlap in many aspects; nonetheless a certain specificity in the cellular response 
can be attributed to the different pathways. In keratinoyctes, JNK is thought to regulate 
proliferation and differentiation, ERK1/2 promotes proliferation and survival, while p38 is 
rather associated with the induction of inflammation, differentiation and apoptosis (Eckert et 
al., 2002; Cargnello and Roux, 2011).  
 
Figure 3: Mammalian TLR signaling pathways. Reproduced with permission from (O'Neill et al., 2013).  
Some TLRs activate another, MyD88-independent signaling pathway for the induction of an 
inflammatory response. Upon TLR stimulation, TRIF is recruited directly to TLR3, and via 
TRAM also to TLR4. In contrast to the MyD88-dependent pathway, TRIF activation leads 
rather to the production of type I interferons, thus enforcing an antiviral response. Briefly, in 
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this pathway TRIF is binding and activating TRAF3 and TRAF6. While TRAF6 activates 
NF-κB and MAPK pathways, TRAF3 induces the activation of IRF3, a transcription factor 
leading to the expression of interferons and other antiviral genes (Kawasaki and Kawai, 
2014).  
 
1.2.3 NF-κB  
NF-κB is a transcription factor that becomes activated in response to cellular stress, for 
example by encounter of pathogens, inflammatory cytokines, UV irradiation or free radicals. 
Five different NF-κB proteins are known, p65 (RelA), RelB, cRel, p50 and p52 (Gilmore, 
2006). The NF-κB family of transcription factors acts as homo- or heterodimers. Dependent 
on the different combinations, NF-κB can act as a transcriptional activator (e.g. dimers 
containing p65 or cRel) or repressor (e.g. p50 or p52 homodimers). Each NF-κB combination 
has a certain specificity to distinct DNA binding sites, thus providing specification of the 
cellular response towards different stimuli (Bonizzi and Karin, 2004). The NF-κB subunits 
are usually bound to a member of the IκB family (IκBα, IκBβ, IκBε, BCL-3) in the 
cytoplasm, rendering them inactive. Pro-inflammatory stimulation of the cell by e.g. IL-1, 
TNF-α or TLR signaling induces the activation of the IKK complex, consisting of IKKα, 
IKKβ and NEMO (Hayden and Ghosh, 2004; Perkins, 2007). In case of TLR and IL-1 
signaling, TRAF6 and TAK1 play a major role during the activation of the IKK complex 
(chapter 1.2.2). The activated IKK complex phosphorylates IκB proteins which leads to their 
quick degradation. This classical pathway releases mostly the NF-κB subunits p50 and p65 
which can then translocate to the nucleus and act as transcription factors. In an alternative 
way (the non-canonical pathway), IKKα is activated by NIK and cleaves the NF-κB 
precursor p100 to its active form p52, which often forms a heterodimer with RelB. Moreover, 
certain stimulations such as UV irradiation or hypoxia have been suggested to induce atypical 
pathways of NF-κB activation by IKK-independent mechanisms such as direct degradation of 
IκB proteins (Perkins, 2007). Additionally, all NF-κB, IκB and IKK subunits are prone to 
extensive post-translational modifications such as phosphorylation, ubiquitination or 
acetylation, which have major impact on the activity, stability and binding specificity of NF-
κB and thus lead to the integration of signals from many different pathways (Perkins, 2006).  
In keratinocytes, NF-κB is involved in the quick inflammatory response of the cell towards 
different stimuli such as encounter of pathogens, cytokine stimulation or UV irradiation 
(Pasparakis, 2009). In mouse models, constituent activation of the NF-κB pathway in 
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keratinocytes by keratinocyte-specific deletion of IκBα or transgenic overexpression of IKKβ 
induces skin inflammation, highlighting the relevance of NF-κB in the inflammatory response 
of keratinocytes (Rebholz et al., 2007; Page et al., 2010). In line with this, in psoriasis, a 
chronic inflammatory skin disease, the NF-κB pathway is highly activated (Johansen et al., 
2005; Lizzul et al., 2005). Moreover, NF-κB has been shown to be crucial for the regulation 
of apoptosis and proliferation in keratinocytes, showing that NF-κB has multiple functions in 
keratinocyte biology (van Hogerlinden et al., 1999; Seitz et al., 2000; Lippens et al., 2011).  
 
1.2.4 Cytokines  
Cytokines are a category of relatively small proteins that transmit signals between different 
cells. In contrast to hormones, cytokines are present in the tissue at rather low concentrations 
(picomolar range), but their expression can be induced very strongly. Functionally, cytokines 
are mostly associated with the regulation of inflammation. They can be secreted by virtually 
all cells of the body, often in response to a stimulus. Cytokines form gradients within the 
tissue around the producing cell, thus influencing neighboring cells in decreasing intensity 
dependent on the distance. The cytokines that are most relevant in skin immunity and during 
the pathogenesis of psoriasis (see also chapter 1.3.2) are briefly described here:  
IL-1 cytokines are closely connected to inflammation and are major mediators of innate 
immunity. The IL-1 family of cytokines consists of 11 members, some of them acting pro-
inflammatory (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ), others anti-inflammatory 
(IL-1ra, IL-36ra, IL-37, IL-38) (Dinarello, 2011). IL-1 cytokines (except IL-1ra) are 
produced as precursors that require intra- or extra-cellular cleavage to gain full biological 
activity.  
IL-1 cytokines bind to a family of receptors, consisting of a combination of a main receptor 
and a co-receptor. IL-1 receptors contain the same intracellular TIR domain as TLRs. Similar 
to the situation in TLR signaling, the binding of IL-1 cytokines (the ligand) to the regarding 
receptor leads to a dimerization with the co-receptor upon which MyD88 is recruited towards 
the intracellular TIR domain of the receptor (O'Neill, 2008). IL-1 cytokines induce therefore a 
very similar signaling cascade as TLR ligands, leading to the activation of the NF-κB and 
MAPK pathways (chapter 1.2.2).  
IL-1α and IL-1β are produced by many cells in a very fast response to tissue injury or 
contact with pathogenic motifs. IL-1α is released upon necrosis, accounting for sterile 
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inflammation (Chen et al., 2007). Virtually all cells express the IL-1α / IL-1β receptors 
IL-1R1 / IL-1R2 and the co-receptor IL1RAcP. Upon encounter of IL-1α or IL-1β, cells react 
with a cell type-dependent strong inflammatory reaction, often involving the additional 
production of IL-1α and IL-1β in a positive feedback-loop (Weber et al., 2010). 
Keratinocytes encountering IL-1 produce a number of immune cell attracting chemokines 
(Sanmiguel et al., 2009). IL-1ra is a receptor antagonist, blocking the IL-1R1 receptor 
without induction of a response. Thus, IL-1ra acts anti-inflammatory. Of note, IL-1 is 
overexpressed in psoriasis lesions (Johnston et al., 2011), and recombinant IL-1ra (anakinra) 
is used off-label successfully for the treatment of pustular psoriasis (Viguier et al., 2010), 
hinting at the relevance of IL-1 signaling in psoriasis.  
IL-36 has three isoforms, IL-36α, IL-36β and IL-36γ. In contrast to IL-1, the IL-36 cytokines 
are expressed majorly in epithelial tissues, such as skin, lung and intestines (Kumar et al., 
2000; Debets et al., 2001). In skin, keratinocytes are a major source of IL-36; they have been 
shown to produce IL-36 upon stimulation with IL-17 (Carrier et al., 2011; Johnston et al., 
2011; Muhr et al., 2011). The receptor for IL-36 is composed of IL-1Rrp2 and the co-receptor 
IL-1RAcP. IL-36 signaling induces a strong activation of NF-κB and MAPK pathways 
including the transcription of downstream targets, suggesting that IL-36 mimics IL-1 
signaling in a tissue-specific basis (Towne et al., 2004). Several immune cells such as 
dendritic cells and monocytes are affected by IL-36 signaling in a pro-inflammatory manner 
(Foster et al., 2014). Murine T cells are skewed towards TH1 differentiation by IL-36 (Vigne 
et al., 2011; Vigne et al., 2012), but this is not reproducible in human T cells which lack the 
IL-36 receptor (Foster et al., 2014). Keratinocytes respond towards IL-36 stimulation with an 
inflammatory response. IL-36 induces NF-κB as well as MEK1/2, JNK and p38 activity in 
keratinocytes (Nguyen et al., 2012), leading to the production of antimicrobial peptides, 
chemokines and cytokines (Carrier et al., 2011; Johnston et al., 2011; Foster et al., 2014). 
IL-36ra is a receptor antagonist that blocks IL-36 signaling, comparable to the function of 
IL-1ra (Towne et al., 2011). IL-38 has been suggested to be another receptor antagonist for 
the IL-36 receptor, although its effect appears to be lower than that of IL-36ra (van de 
Veerdonk et al., 2012).  
IL-36 has been closely connected to the pathogenesis of psoriasis. IL-36 cytokines are 
overexpressed in psoriasis skin lesions (Debets et al., 2001; Blumberg et al., 2007; Johnston 
et al., 2011), while mutations of the anti-inflammatory receptor antagonist IL-36ra are 
associated with the development of pustular psoriasis (Marrakchi et al., 2011; Onoufriadis et 
al., 2011). Strikingly, transgenic mice overexpressing IL-36α in keratinocytes develop a 
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psoriasis-like skin phenotype. Additional deletion of IL-36ra worsens this phenotype, 
showing the relevance of IL-36 signaling in skin inflammation (Blumberg et al., 2007). 
Altogether, the IL-36 cytokines appear to be tissue-specific inducers of innate inflammation 
and their de-regulation in psoriasis renders them as attractive therapeutic targets.  
TNF-α is a very potent pro-inflammatory cytokine that is produced in the skin predominantly 
by mast cells and macrophages, but also by T cells and keratinocytes (Carswell et al., 1975; 
Kock et al., 1990). Its receptor is expressed on virtually all cells, inducing different pathways: 
Most relevant is the activation of NF-κB, which leads to an inflammatory response of the 
target cell. In addition, differentiation and proliferation is induced through the JNK MAPK 
pathway, while apoptosis is promoted via caspase-dependent pathways (Bradley, 2008; 
Aggarwal et al., 2012). The large influence of TNF-α on inflammation has made it an 
attractive target for therapy of inflammatory diseases. Indeed, monoclonal antibodies 
(infliximab, adalimumab) or soluble receptors (etanercept) targeting TNF-α are successfully 
used in the clinical treatment of psoriasis but also in other chronic inflammatory diseases 
(Krueger and Callis, 2004).  
IL-23 is produced by activated dendritic cells and macrophages, in the skin possibly also by 
keratinocytes (Piskin et al., 2006). IL-23 contributes to the TH17 lineage commitment during 
T cell differentiation and maintenance, thus favoring the TH17 effector response during 
inflammation (Wilson et al., 2007). IL-23 has been implicated to contribute majorly to the 
pathogenesis of chronic inflammation, such as in psoriasis (Chan et al., 2006). An antibody 
targeting the p40 subunit of IL-23 (ustekinumab) is used clinically for the treatment of 
psoriasis (Gaffen et al., 2014).  
IL-17 is the originally defining cytokine of TH17 cells. In addition to TH17 cells, also other 
cells such as γδT cells and innate lymphoid cells can produce IL-17 in the skin (Cua and 
Tato, 2010). Neutrophils have recently been shown to be a relevant source of IL-17, 
especially in psoriasis lesions (Lin et al., 2011; Keijsers et al., 2014). IL-17 acts as a pro-
inflammatory cytokine, inducing the production of various cytokines, chemokines and 
colony-stimulating factors (e.g. IL-1β, IL-6, IL-8, CXCL1, GM-CSF) in a range of cells, 
among them macrophages and keratinocytes (Korn et al., 2009). IL-17 is a central cytokine in 
the pathogenesis of psoriasis, as evidenced by the efficacy of anti-IL-17 / IL-17 receptor 
antibodies in clinical trials (Chiricozzi and Krueger, 2013). 
IL-22 is an effector cytokine which is produced by various immune cells, especially by TH1, 
TH17 and TH22 cells (Rutz et al., 2013). Interestingly, IL-22 targets mainly epithelial cells, in 
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the skin keratinocytes (Wolk et al., 2009). IL-22 induces the production of a series of 
antimicrobial peptides and granulocyte-attracting chemokines, supporting a role in anti-
bacterial defense mechanisms. Moreover, it suppresses the differentiation process of 
keratinocytes, possibly supporting repair mechanism in the skin (Sabat et al., 2014). All these 
processes are disturbed in psoriasis, making IL-22 a highly relevant target in therapeutic 
approaches.  
TGF-β is a multipotent cytokine that has a strong chemoattractant potential. TGF-β is 
produced by many cell types, including immune cells and keratinocytes. It controls 
proliferation, differentiation, immunity and other cellular functions in a highly context-
specific manner via SMAD signaling (Massague, 2012). In inflammatory processes, TGF-β 
acts both stimulatory and inhibitory, likely orchestrating a balance between inflammation and 
homeostasis (Wahl, 1994). In keratinocytes, TGF-β signaling promotes homeostasis by 
suppressing proliferation, and supports re-epithelialization during wound healing (Shirakata, 
2010; Ramirez et al., 2014). Keratinocyte-specific overexpression of TGF-β1 in a mouse 
model leads to psoriasis-like skin inflammation, suggesting a substantial contribution of 
TGF-β to the pathogenesis of psoriasis (Liu et al., 2001; Han et al., 2010).  
IFN-γ is a key cytokine produced by TH1 cells. IFN-γ induces an antiviral state via IRF 
transcription factors in a variety of cells (Schroder et al., 2004). In keratinocytes, IFN-γ leads 
to the increased production of chemokines, cell adhesion molecules and HLA genes, which is 
in accordance with its antiviral function (Banno et al., 2003). In psoriasis, IFN-γ is highly 
overexpressed (Kaneko et al., 1990).  
 
1.2.5 Chemokines 
Chemokines are small peptides, which can induce directed chemotaxis in nearby responsive 
cells, thus contributing to the intercellular communication (Griffith et al., 2014). More than 
40 chemokines in different structural families are known today. While some chemokines are 
constitutively expressed, most are of inflammatory nature and are secreted only upon 
stimulation. The secretion of chemokines by a cell leads to the formation of a chemotactic 
concentration gradient within the tissue. Migratory cells with regarding chemokine receptors 
follow this gradient and are thus attracted to the chemokine producing cell. The chemotactic 
gradient reaches also the blood vessels and can therefore attract circulating immune cells 
from the blood stream into the tissue at a specific site (Comerford and McColl, 2011). 
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Different cell types express different sets of chemokine receptors; therefore the secretion of a 
certain chemokine mixture will attract specific immune cells.  
In the skin, keratinocytes are a major source of chemokines during inflammation (Mabuchi et 
al., 2012; Singh et al., 2013b). Upon tissue damage or infection, keratinocytes produce 
chemokines which are secreted to the extracellular space (Figure 2). Their production and 
secretion leads to the activation of endothelial cells and to the chemotactic attraction of 
immune cells, in particular neutrophils, monocytes/macrophages, eosinophils, T cells and 
dendritic cells into the skin.  
Highly relevant in skin immunity are the chemokines IL-8 (also known as Neutrophil-
activating peptide; NAP, systematic name: CXCL8), CXCL1 (Growth regulated oncogene-α; 
GROα) and CXCL2 (Growth regulated oncogene-β; GROβ) which attract and activate 
neutrophils expressing the receptors CXCR1 and CXCR2 (Larsen et al., 1989; Schumacher et 
al., 1992). IL-8 is also known to be a potent promoter of angiogenesis (Koch et al., 1992). 
The keratinocyte-produced chemokine CCL20 (Macrophage inflammatory protein-3α; MIP-
3α) is the only ligand of CCR6 (Baba et al., 1997; Power et al., 1997). A large number of 
immune cells expresses CCR6 (Schutyser et al., 2003), among them TH17 cells and 
regulatory T cells, but not TH1 or TH2 cells (Yamazaki et al., 2008), showing that CCL20 
may attract only a specific subset of T cells to the skin. CCL5 (Regulated on activation, 
normal T cell expressed and secreted; RANTES) attracts cells which express the receptors 
CCR1, CCR3 or CCR5 (monocytes, dendritic cells, TH cells, basophils, eosinophils, 
neutrophils, NK cells, mast cells). CCL5 therefore attracts a very mixed population of 
immune cells. CCL5 and its receptors CCR1/3/5 have been targeted for therapeutic 
approaches in infectious and autoimmune diseases (Marques et al., 2013). The interferon-
inducible chemokines CXCL9 (Monokine induced by gamma interferon; MIG), CXCL10 
(Interferon gamma-induced protein 10; IP-10) and CXCL11 (Interferon-inducible T-cell 
alpha chemoattractant; I-TAC) all recruit effector T cells by their receptor CXCR3, thus 
enforcing an antiviral reaction (Groom and Luster, 2011). CCL27 (Cutaneous T-cell-
attracting chemokine; CTACK) attracts skin-homing T cells via CCR10. Interestingly, a 
majority of T cells in inflamed skin expresses CCR10, a phenotype that is not seen in other 
organs (Morales et al., 1999; Homey et al., 2002).  
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Table 1: Examples of keratinocyte-derived chemokines and their function   
Chemokine corresponding chemokine receptor Cell type attracted 
IL-8  
CXCL1  
CXCL2  
CXCR1 / CXCR2 Neutrophils 
CCL20 CCR6 TH17 cells, Treg cells, dendritic cells, monocytes  
CCL5 CCR1 / CCR3 / CCR5 monocytes, dendritic cells, TH cells, basophils, eosinophils, neutrophils, NK cells, mast cells 
CXCL9  
CXCL10  
CXCL11 
CXCR3 T cells 
CCL27 CCR10 T cells 
CCL2 CCR2 monocytes, TH1 cells  
CCL17 CCR4 TH1, TH17 cells  
 
In addition to leukocytes, also endothelial cells express a series of chemokine receptors. 
Keratinocyte-derived chemokines can activate endothelial cells, thus facilitating the 
extravasation of leukocytes from the circulation into the tissue, but also enforce angiogenesis 
which leads to the formation of new blood vessels in the inflamed tissue (Speyer and Ward, 
2011).  
The mixture of chemokines secreted by keratinocytes upon inflammatory stimulation (e.g. by 
TLR ligands, cellular stress or cytokine signaling), can attract specific subsets of immune 
cells in a coordinated timely manner. Normally, the secretion of chemokines by keratinocytes 
is only transient, thus enabling the restoration of homeostasis after clearance of the inducing 
trigger. However, in psoriasis skin lesions the described chemokines are up-regulated 
(Mabuchi et al., 2012; Singh et al., 2013b), supporting a role for chemokines in sustaining 
chronic inflammation by constantly recruiting immune cells to the skin.  
 
1.2.6 Antimicrobial peptides  
Antimicrobial peptides (AMPs) are important components of the innate immune system to 
control infections. AMPs can destroy pathogens by various direct and indirect mechanisms, 
targeting bacteria, viruses, fungi and protozoa (Izadpanah and Gallo, 2005). Electrostatic 
interaction of positively charged AMPs with the negatively charged membrane of a microbe 
leads to the formation of pores and to the disruption of the membrane, thus killing the 
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microbe within seconds (Loeffler et al., 2001). AMPs also interact with and inhibit microbial 
proteins and disturb DNA or RNA synthesis (Bahar and Ren, 2013). In the skin, 
keratinocytes are a major source of AMPs, the most important being β-defensins, S100 
proteins and the cathelicidin LL-37 (Bardan et al., 2004). Interestingly, in psoriasis many 
AMPs are highly overexpressed, which has recently been implicated in the disease 
pathogenesis (chapter 1.3.2) (Morizane and Gallo, 2012). Moreover, increased genomic copy 
numbers of β-defensin genes were associated with the risk to develop psoriasis, suggesting a 
functional connection (Hollox et al., 2008).  
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1.3 PSORIASIS  
Psoriasis is a chronic inflammatory skin disease which affects approximately 2-3 % of the 
worldwide population (Lowes et al., 2007). The prevalence of psoriasis differs between 
populations, peaking in northern Europe and being significantly less common in Asia and 
South America (Christophers, 2001). Psoriasis is a life-long disease with significant impact 
on the quality of life (Dowlatshahi et al., 2014; Ronneberg Mehren et al., 2014). Disease 
onset can occur at any age but is most common in young adults. Although treatment options 
have increased during the past years, no cure is known for psoriasis. The most common type, 
psoriasis vulgaris (plaque type psoriasis), is characterized by erythematous plaques of the 
skin with well-defined borders and silvery scales (Figure 4). Less common phenotypes 
include guttate, inverse, pustular, erythrodermic and palmo-plantar psoriasis.  
Figure 4: Psoriasis plaques.  
Histologically, plaque psoriasis lesions show an increased thickening of the epidermis, in 
conjunction with incomplete keratinocyte differentiation of the upper layers, leading to the 
retention of nuclei in the stratum corneum (Figure 5). The basal layers of the epidermis are 
characterized by increased keratinocyte proliferation and elongated epidermal rete ridges. 
More dermal blood vessels are formed, responsible for the redness of the lesions. Moreover, a 
massive immune cell infiltrate can be observed in both dermis and epidermis, containing T 
cells, dendritic cells and others. Very characteristic is the presence of neutrophils in the 
epidermis and especially in the stratum corneum (Perera et al., 2012; Lowes et al., 2014).  
Patients affected by psoriasis often develop co-morbidities. Nail dystrophy, psoriatic arthritis, 
depression, Crohn’s disease, squamous cell carcinoma and lymphoma are associated with 
psoriasis. Recently, also cardiovascular diseases, diabetes and metabolic syndrome / obesity 
have been epidemiologically associated with psoriasis (Lowes et al., 2014). The connection 
of the skin disease psoriasis with seemingly not skin related systemic diseases reveals that 
psoriasis may affect the whole organism and systemic inflammation may be an 
underestimated problem in psoriasis patients.  
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Figure 5: Histological section of healthy skin (left) and psoriasis lesional skin (right).  
In psoriasis, a complex interplay between the different cell types in the skin causes chronic 
inflammation. The underlying cause of psoriasis is unknown, but both genetic risk factors as 
well as environmental triggers have been identified to contribute to the pathogenesis of 
psoriasis.  
 
1.3.1 The genetic background of psoriasis  
Psoriasis has a high concordance rate in monozygotic twins (up to 70 %) compared to 
dizygotic twins (up to 20 %), suggesting a strong genetic component in disease pathogenesis 
(Bowcock, 2005). Nonetheless, the lack of complete inheritance in monozygotic twins 
indicates that additional factors contribute to the development of psoriasis.  
Up till now, 36 different psoriasis susceptibility loci have been identified over the past years 
(Tsoi et al., 2012). The genetic locus PSORS1 on chromosome 6 shows the strongest 
association to psoriasis with HLA-Cw*0602 as the main disease causing variant (Nair et al., 
2006). HLA-C is expressed by dendritic cells to present antigens to CD8pos T cells. But also 
keratinocytes express HLA-C and are thought to interact via this molecule with NK cells 
(Dunphy and Gardiner, 2011). Linkage analysis in families as well as large-scale genome-
wide association studies (GWAS) have identified other susceptibility loci, most of which 
involve genes that are connected to immune responses (Nair et al., 2009; Zhang et al., 2009; 
Ellinghaus et al., 2010; Genetic Analysis of Psoriasis et al., 2010; Tsoi et al., 2012). Genetic 
loci with a number of genes involved in the NF-κB pathway (e.g. TNFAIP3, TNIP, 
TRAF3IP2, NFKBIA) were shown to be associated with the risk to develop psoriasis, 
suggesting a major contribution of the innate immune system to psoriasis pathogenesis (Tsoi 
et al., 2012). In line with this, genetic mutations of CARD14, a regulator of the NF-κB 
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pathway, were shown to be causal for the development of psoriasis in several families (Jordan 
et al., 2012). Genetic deletion of late cornified envelope (LCE) genes which are relevant for 
the differentiation of keratinocytes have also been associated with the risk to develop 
psoriasis, thus presenting a genetic connection of a skin-specific gene (de Cid et al., 2009).  
In some families mutations of IL-36ra have been reported to be associated with a rare 
phenotype of psoriasis, pustular psoriasis. The anti-inflammatory effect of IL-36ra was 
decreased by the mutation, likely explaining the development of severe inflammatory 
pustular psoriasis in these patients (Marrakchi et al., 2011; Onoufriadis et al., 2011). Thus, 
even though psoriasis is generally considered as a complex genetic disease, some phenotypes 
may appear as monogenic disease traits, indicating that psoriasis is highly heterogeneous and 
associated with a variety of underlying causes and triggers. Interestingly, association of 
certain risk loci seems also to depend on the age of disease onset, suggesting that a strict 
stratification of study populations might be needed to reveal underlying genetic causes of 
psoriasis (Lysell et al., 2013).  
 
1.3.2 The pathogenesis of psoriasis  
The pathogenesis of psoriasis is not fully understood, but evidence from extensive research 
has led to a model where interaction of multiple cell types within the skin establishes a cycle 
of chronic inflammation. This process has been described as the IL-23 / TH17 / IL-22 axis of 
psoriasis (Di Cesare et al., 2009; Nestle et al., 2009b) (Figure 6).  
Psoriasis can be triggered by several environmental stimuli, all of them also known to worsen 
the ongoing disease. Infections, especially by streptococci, physical trauma and certain 
medications can trigger psoriasis (Abel et al., 1986; Raychaudhuri et al., 2008; Valdimarsson 
et al., 2009). In conjunction with a certain genetic background rendering a person susceptible 
to psoriasis, these and other triggers may lead to cellular stress in the skin, inducing an 
inflammatory response of local keratinocytes. Activated keratinocytes produce large amounts 
of antimicrobial peptides such as LL-37 (Frohm et al., 1997). LL-37 can form complexes 
with self-DNA which may be released from necrotic cells in the stressed skin. These LL-37 / 
DNA complexes can trigger the activation of plasmacytoid dendritic cells (pDCs) in a TLR7 / 
TLR8 / TLR9-dependent manner (Lande et al., 2007; Ganguly et al., 2009). Also other 
antimicrobial peptides secreted by keratinocytes (β-defensin-2, β-defensin-3, lysozyme) can 
complex with DNA and activate pDCs in a TLR9-dependent fashion (Lande et al., 2014), 
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thus potentially breaking the immunological tolerance of the skin. pDCs release IFN-α upon 
activation (Cella et al., 1999), which has clinically been shown to induce psoriasis (Funk et 
al., 1991) and is present at increased concentrations in psoriasis lesions (Nestle et al., 2005; 
Yao et al., 2008). Myeloid dendritic cells (mDCs) may become activated in the local 
inflammatory milieu and migrate to the draining lymph nodes where they activate T cells, 
although it remains debatable what antigen might be presented during this interaction. 
Activated mDCs, but also keratinocytes produce high levels of IL-23, which favors the 
polarization and maintenance of TH17 cells and can be found at increased concentrations in 
psoriasis lesions (Piskin et al., 2006; Wilson et al., 2007; McGeachy et al., 2009). 
Neutralization of IL-23 by monoclonal antibodies is used successfully in the treatment of 
psoriasis (ustekinumab) (Gandhi et al., 2010), suggesting that IL-23 indeed has a major 
impact on the pathogenesis of psoriasis.  
TH17 as well as TH22 cells express CCR6 and can thus be attracted via keratinocyte-produced 
CCL20 to the skin (Trifari et al., 2009; Mabuchi et al., 2012). In this model, activated TH17 
and TH22 cells migrate towards the skin and contribute to an inflammatory reaction. 
Accordingly, TH17 and TH22 cells are abundant in psoriasis lesions and have been implicated 
to play a driving role in many autoimmune disorders (Lowes et al., 2008; Eyerich et al., 2009; 
Singh et al., 2014). TH17 and TH22 cells produce a series of pro-inflammatory cytokines, 
most prominent IL-17 and IL-22, which have major effects on keratinocytes. The activation 
of keratinocytes by IL-17 and IL-22 leads to hyperproliferation (Zheng et al., 2007; Wolk et 
al., 2009; Rizzo et al., 2011) and to the production of chemokines (Albanesi et al., 2000; 
Homey et al., 2000; Wolk et al., 2004; Boniface et al., 2005) which in turn attract more 
immune cells into the skin. Thus, a vicious cycle of continuous inflammation is initiated, 
leading to the observed clinical phenotype of psoriasis lesions.  
Many pro-inflammatory chemokines are up-regulated in psoriasis skin lesions and influence 
the cellular composition in the skin (Mabuchi et al., 2012). CCL20 for example is 
overexpressed in psoriasis skin (Homey et al., 2000). Its selective attraction of CCR6pos cells 
could explain the massive infiltrate of TH17 cells in psoriasis lesions (Yamazaki et al., 2008). 
Keratinocytes in psoriasis lesions produce also increased levels of CCL2, which attracts 
monocytes via CCR2 (Vestergaard et al., 2004). The overexpression of IL-8 (CXCL8) in 
psoriasis lesions could account for the massive infiltration of neutrophils into the epidermis 
via CXCR1 / CXCR2 (Gillitzer et al., 1996).  
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Figure 6: Model of the pathogenesis of psoriasis by the IL-23/TH17/IL-22 axis. Reproduced with permission 
from (Nestle et al., 2009b). Copyright Massachusetts Medical Society.  
The relevance of the intercellular communication for disease pathogenesis is seen in the 
recent development of drugs targeting the mentioned pathways, so called biologics. Drugs 
targeting TNF-α and the p40 subunit of IL-12 / IL-23 are readily used in clinical practice, 
while drugs against IL-17, the IL-17 receptor and the IL-23 p19 subunit are recently in 
clinical trials (Leonardi et al., 2015). The cross-talk between keratinocytes and immune cells 
becomes also obvious in mouse models where the keratinocyte-specific deletion of a disease-
relevant gene has systemic effects that are modulated by the immune system (Wagner et al., 
2010). For example mice with a keratinocyte-specific knock-out of c-Jun and JunB develop 
psoriasis-like inflammation in the skin, but also arthritis which is mediated by T and B cells 
(Zenz et al., 2005). On the other hand, in a model of xenotransplantation of human skin onto 
SCID mice, psoriasis non-lesional skin can be induced to develop full-fledged psoriasis 
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plaques upon dermal injection of activated immune cells, suggesting that the cells of the 
immune system influence the behavior of keratinocytes (Wrone-Smith and Nickoloff, 1996).  
Many other cell types are involved in the cross-talk during chronic inflammation, and many 
of the connections between the cells are not well understood. Nonetheless, this currently most 
accepted model of psoriasis pathogenesis explains many of the manifestations seen in 
psoriasis patients.  
In healthy skin, a similar inflammatory reaction might be induced by environmental triggers 
(Stamatas et al., 2013). However, in difference to patients affected by psoriasis, upon 
clearance of the inducing trigger, the inflammation is resolved and the skin returns back to 
homeostasis. Why these mechanisms fail in psoriasis patients remains unclear. Genetic 
predispositions as described above are part of the explanation, but this cannot in all cases 
account for the lack of resolution of inflammation.  
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1.4 NON-CODING RNAS  
The human genome consists of approximately 3 billion base pairs, but only 1-2 % are 
encoding for protein-coding genes (Lander et al., 2001). While the rest of the genome was 
originally considered as “junk DNA”, it is becoming increasingly recognized that the vast 
majority of the DNA has functional relevance besides structural stability (Claverie, 2005). 
Large-scale sequencing projects have revealed that at least 80 % of the genome has functional 
relevance, being transcribed into RNA or physically interacting with proteins (Consortium, 
2012). A surprisingly large variety of RNAs is actively transcribed and can be grouped into 
several categories. Besides the protein-coding genes (mRNAs), a very heterogeneous group 
of non-coding RNAs with diverse functionality is present in cells (Morris and Mattick, 2014). 
Often forgotten, tRNAs and rRNAs are non-coding RNAs that fulfill basic functions in the 
cellular metabolism during translation from mRNA to protein, they belong to the most 
important housekeeping genes. Also active in the basic metabolism are small nuclear RNAs 
(snRNA) including small nucleolar RNAs (snoRNAs), which are involved in the splicing of 
mRNA (Matera et al., 2007).  
The field of regulatory RNAs has been emerging with advances in sequencing technologies 
and large scale analysis of non-coding RNAs. MicroRNAs (miRNAs) are the most prominent 
and best studied regulatory RNAs (chapter 1.4.1). Other regulatory non-coding RNAs 
include Piwi-interacting RNAs (piRNAs), which are thought to sustain genomic integrity by 
the repression of retrotransposons (Luteijn and Ketting, 2013). Long non-coding RNAs 
(lncRNAs) are a very heterogeneous group of RNAs longer than 200 nucleotides, but 
spanning up to several thousands of nucleotides. They can be located in intergenic or intronic 
regions of the genome, but they can also be a sense or antisense transcript from known 
mRNAs. LncRNAs regulate gene expression by a variety of mechanisms, often acting as a 
scaffold for other molecules, connecting proteins, genomic DNA, mRNAs and other 
regulatory RNAs (Fatica and Bozzoni, 2014). Recently, a novel class of circular RNAs 
(circRNAs) has been discovered. Functionally, one of the circRNAs was shown to be 
involved in the intracellular transportation of miRNAs, suggesting yet an additional 
mechanism of gene regulation by RNAs (Memczak et al., 2013).  
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1.4.1 microRNAs  
MicroRNAs (miRNAs) are 20-23 nucleotide long single-stranded RNA molecules that 
regulate gene expression by post-transcriptional silencing of a specific set of target genes. 
The discovery of the first miRNA (lin-4) (Lee et al., 1993) was originally regarded as a 
peculiarity of the worm Caenorhabditis elegans. The second miRNA to be known (let-7) was 
identified several years later, again in Caenorhabditis elegans (Reinhart et al., 2000), but 
shortly after, it became apparent that miRNAs are a whole class of short non-coding RNAs 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). Nowadays, more than 
2500 miRNAs are known in human (Kozomara and Griffiths-Jones, 2014).  
 
Figure 7: The biogenesis of miRNAs. Reproduced with permission from (Sonkoly and Pivarcsi, 2009).  
 
MiRNAs are usually encoded by genes containing promoters and transcription factor binding 
sites and are transcribed by the RNA polymerase II, just like protein-coding genes (Ha and 
Kim, 2014) (Figure 7). The expression of miRNAs therefore underlies classical 
transcriptional regulation (Lee et al., 2004). The primary miRNA transcript (pri-miRNA) is 
processed in the nucleus by DGCR8 and the endonuclease Drosha to a ~ 70 nucleotide long 
miRNA precursor (pre-miRNA) (Lee et al., 2003). The pre-miRNA forms a hairpin structure 
and is exported from the nucleus by Exportin 5 coupled to Ran-GTP (Yi et al., 2003; Lund et 
al., 2004). In the cytoplasm, the hairpin of the pre-miRNA is further cleaved by the enzyme 
Dicer, leaving a short double-stranded RNA duplex (Ketting et al., 2001). One of the two 
strands, the mature miRNA, is subsequently incorporated into the RNA-induced silencing 
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complex (RISC) that contains proteins of the argonaute (Ago) family as central components 
(Hutvagner and Zamore, 2002). The miRNA within the RISC complex then binds to the 3'-
UTR of its target gene. This binding can be imperfect, but requires the seed sequence 
(nucleotide 2-8 of the miRNA) to be fully complementary. Upon this binding the target 
mRNA is either degraded, or protein translation is inhibited, in both cases leading to reduced 
protein expression (Huntzinger and Izaurralde, 2011). Predictions about which mRNAs are 
directly targeted by a miRNA are challenging, due to the short seed sequence and the 
imperfect base pairing between miRNA and mRNA (Brennecke et al., 2005; Brodersen and 
Voinnet, 2009). 
Many miRNAs are evolutionary highly conserved from worm to human (Lau et al., 2001). 
Interestingly, also many miRNA binding sites in the 3'-UTR of mRNAs are highly conserved, 
hinting at a solid co-evolution (Friedman et al., 2009). Some miRNAs which share major 
sequence similarities especially in the functionally relevant seed sequence are categorized in 
miRNA families. MiRNAs belonging to the same family are often encoded in close 
proximity within the genome, thus forming clusters (Altuvia et al., 2005; Mathelier and 
Carbone, 2013).   
MiRNAs are estimated to regulate the expression of more than 60 % of all genes, it is thus 
not surprising that miRNAs have been implicated to affect virtually all biological processes 
(Friedman et al., 2009). A single miRNA regulates dozens to hundreds of genes (Krek et al., 
2005; Lim et al., 2005; Friedman et al., 2009). Usually, the target genes are repressed by a 
miRNA only modestly (Baek et al., 2008; Selbach et al., 2008). However, since the targets of 
a miRNA often belong to the same biological pathways (Grun et al., 2005; Lall et al., 2006), 
a miRNA may have a major effect on the overall functional behavior of a cell. MiRNAs have 
therefore been attributed as fine-tuners of gene expression which keep the protein 
concentration of all its targets in the precise optimal range and thus contribute to tissue 
homeostasis (Bartel, 2004, 2009).  
The miRNA signature is often tissue-specific (Lim et al., 2005; Sood et al., 2006); it has been 
suggested that miRNAs suppress the expression of all genes that should not be present in a 
certain tissue to inconsequential levels, therefore contributing to tissue identity (Bartel and 
Chen, 2004). MiRNAs play a crucial role during development, as demonstrated by the fact 
that mice without miRNAs (knock-out of Dicer or DGCR8) are not viable (Bernstein et al., 
2003; Wang et al., 2007). Also deletion of a single miRNA can lead to severe developmental 
defects, as shown by for example neonatal lethality of miR-205 knock-out mice (Wang et al., 
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2013). But in most cases the deletion of a single miRNA in vivo has little or no effect on 
viability, and for many miRNA deletions no obvious phenotype has been reported (Park et 
al., 2010). Redundancies with other miRNAs, potentially from the same family, may account 
for this observation, nonetheless it has been noted that many miRNA knock-out mice display 
an altered phenotype only upon injury or stress (Mendell and Olson, 2012). For example 
miR-22 knock-out mice do not exhibit any obvious phenotype, but upon external stress 
(isoproterenol treatment), the miR-22 knock-out mice are prone to develop cardiomyopathies 
(Huang et al., 2013). These observations support the hypothesis that a main function of 
miRNAs is to maintain cellular homeostasis upon external instabilities.  
 
1.4.2 microRNAs in diseases  
MiRNAs have been shown to be deregulated in a large variety of human diseases. In many 
different types of cancer substantial differences in the miRNA expression profile were 
detected; moreover, the discovery of specific oncogenic miRNAs (onco-miRs) and tumor 
suppressor miRNAs has shed light on the significance of miRNAs during tumorigenesis (Lu 
et al., 2005; Garzon et al., 2009; Iorio and Croce, 2012). MiRNAs are deregulated in and 
have been implicated to impact several autoimmune diseases, among them psoriasis (chapter 
1.4.3), rheumatoid arthritis, diabetes, multiple sclerosis, systemic lupus erythematosus, 
Sjögrens syndrome, inflammatory bowel disease (Pauley et al., 2009; Ceribelli et al., 2012; 
Singh et al., 2013a; Qu et al., 2014). MiRNAs are also involved in other disease types, for 
example in cardiovascular diseases (Hata, 2013) or neurodegenerative disorders (Abe and 
Bonini, 2013). Interestingly, miRNA expression profiles have been shown to robustly classify 
various cancers, while mRNA expression profiles from the same samples were inaccurate, 
proposing miRNAs as potential biomarkers (Lu et al., 2005).  
In recent years, it has been shown that most cells release miRNAs to the extracellular 
environment, either packaged in vesicles / exosomes, or bound to protein complexes 
protecting from the degradation by RNases, thus being remarkably stable (Valadi et al., 2007; 
Arroyo et al., 2011). Exosomal miRNAs were shown to be taken up and processed by other 
cell types, thus representing a novel mode of communication between cells (Valadi et al., 
2007). Extracellular miRNAs can be detected in various body fluids such as serum, which 
makes them interesting as easily accessible potential biomarkers (Chen et al., 2008; Mitchell 
et al., 2008). Indeed, serum miRNAs were acknowledged to distinguish between health and 
disease in a large number of disorders, especially cancers (Reid et al., 2011), though a lack of 
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disease specificity has been an issue with this approach so far (Witwer, 2014). Moreover, 
miRNAs have been discussed to predict therapy response, which might improve clinical 
treatment options (Schwarzenbach et al., 2014).  
MiRNAs have early on been proposed as promising therapeutic targets. Since many miRNAs 
target a large number of genes involved in the same biological pathways, a fine-tuned 
restoration of the healthy state could possibly be achieved by miRNA therapeutics. Moreover, 
due to the large number of miRNA targets the risk to develop drug resistances in cancer is 
considered to be relatively low (Broderick and Zamore, 2011; van Rooij et al., 2012). Drugs 
targeting several different miRNAs have been developed for the treatment of various 
diseases, and the first ones are already in clinical trials (miR-122 inhibition for treatment of 
hepatitis C; inhibition of miR-34 for treatment of hepatic cancer) (van Rooij and Kauppinen, 
2014). These encouraging results hold promise for the development of novel therapeutic 
strategies also in chronic inflammatory diseases.  
 
1.4.3 microRNAs in psoriasis  
Our group has previously analyzed the miRNA expression profile of psoriasis lesional skin 
and identified a set of miRNAs to be differentially expressed (Sonkoly et al., 2007). The 
miRNA profile of psoriasis skin lesions has been confirmed by other studies (Zibert et al., 
2010; Joyce et al., 2011; Lerman et al., 2011). We have also studied the level of circulating 
miRNAs in serum of psoriasis patients and found four miRNAs to be changed compared to 
healthy controls (Pivarcsi et al., 2013). In full blood another panel of miRNAs was shown to 
be differentially expressed between psoriasis patients and healthy individuals (Lovendorf et 
al., 2014).  
Several of the miRNAs which are de-regulated in psoriasis skin lesions have been studied in 
functional detail: MiR-203 was identified as the first skin-specific miRNA by our group 
which is up-regulated in psoriasis and was shown to regulate keratinocyte differentiation (Yi 
et al., 2008; Sonkoly et al., 2010). We have shown that miR-125b is down-regulated in 
psoriasis and regulates proliferation and differentiation of keratinocytes (Xu et al., 2011). We 
have also identified miR-21 to be up-regulated in psoriasis and to suppress T cell apoptosis 
(Meisgen et al., 2012). Interestingly, targeting of miR-21 in mouse models of psoriasis by 
miRNA inhibitors could ameliorate the disease phenotype and showed a similar efficacy as 
anti-TNF therapy (Guinea-Viniegra et al., 2014). This shows the pathogenic role of 
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deregulated miRNAs in vivo and demonstrates the potential of miRNA-based drugs in the 
treatment of psoriasis. Several other miRNAs have been identified in psoriasis, for example 
miR-424 (Ichihara et al., 2011) and miR-99a (Lerman et al., 2011), which both affect the 
proliferative capacity of keratinocytes. Altogether, these studies highlight the relevance of 
miRNAs in psoriasis and their potential involvement during disease pathogenesis.  
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2 AIMS 
This thesis aims to explore the role of miRNAs in skin immunity and psoriasis. The intention 
of this work is to understand the regulation and function of miRNAs in skin immunity and 
their contribution to pro- or anti-inflammatory processes during the innate immune reactions 
of keratinocytes.  
 
In particular the objectives of this work are:  
 to identify miRNAs involved in the innate immune response of keratinocytes (Paper I),  
 to study the role of miR-146a in the innate immune function of keratinocytes (Paper II),  
 to explore the role of miR-146a in psoriasis (Paper III), and 
 to investigate the regulation and function of miR-31 in psoriasis (Paper IV).  
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3 MATERIALS AND METHODS 
Skin biopsies  
Four-millimeter punch biopsies were taken from non-lesional and lesional skin of patients 
with moderate to severe chronic plaque psoriasis, and from noninflamed, nonirritated skin of 
healthy individuals. The psoriasis patients had not received systemic immunosuppressive 
treatment or psoralen + UVA / solarium / UV for at least one month and topical therapy for at 
least two weeks before skin biopsy. The clinical material was obtained after informed consent 
and the study was approved by the Stockholm Regional Ethics Committee and conducted 
according to the Declaration of Helsinki’s principles.  
Isolation of CD45neg epidermal cells  
Freshly taken biopsies were incubated in dispase (5 U/ml) over night at 4°C to separate 
dermis and epidermis. The epidermal sheets were digested with a trypsin / EDTA mixture for 
15 minutes at 37°C to obtain a single-cell suspension. In order to isolate CD45neg epidermal 
cells, CD45pos cells were marked with CD45-microbeads and depleted from the cell 
suspension using MACS MS magnetic columns according to manufacturer’s intructions 
(Milteney Biotec, Bergisch Gladbach, Germany).  
In situ hybridization  
In situ hybridization was performed using slightly different protocols for different miRNAs. 
For visualization of miR-146a expression, formalin-fixed paraffin embedded sections (10 µm 
thickness) of skin biopsies were de-paraffinized, incubated for 15 minutes at 37°C with 
proteinase K (20 µg/ml) and hybridized with a miR-146a-specific digoxigenin-labeled 
miRCURY locked nucleic acid probe (25 nM) (Exiqon, Vedbaek, Denmark) over night at 
55°C. The slides were then washed with 5× saline-sodium citrate (SSC) buffer for 15 minutes 
and twice with 0.2× SSC for 30 minutes at hybridization temperature. The sections were 
incubated with alkaline phosphatase-conjugated sheep anti-digoxigenin Fab fragments 
(1:1500 [Roche, Basel, Switzerland]) for one hour at room temperature. The probe was 
visualized by adding BM purple alkaline phosphatase substrate (Roche) according to the 
manufacturer’s instructions. MiR-31 expression was visualized using frozen skin sections (10 
µm thickness). The sections were incubated with acetylation solution (60 mM HCl, 1.3% 
trietanolamin and 0.6% acetic anhydride in DEPC treated water) for 10 minutes at room 
temperature and permeabilization buffer (1% Triton X-100) for 30 minutes at room 
temperature. Hybridization with 25 nM digoxigenin-labeled miRCURY locked nucleic acid 
probes (Exiqon) was performed over night at 50°C. Slides were then washed four times with 
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2× SSC buffer followed by one time with 0.1× SSC buffer at 67°C. The probe binding was 
detected by incubating the sections with alkaline phosphatase-conjugated sheep anti-
digoxigenin Fab fragments (1:2500) for one hour at room temperature. The probe was 
visualized using BM purple alkaline phosphatase substrate.  
Immunohistochemistry 
STK40 protein expression was analyzed in both frozen and formalin-fixed paraffin embedded 
skin sections (7 µm in thickness) using rabbit anti-human STK40 antibody (1:200; Sigma-
Aldrich, St. Louis, MO, USA) and the avidin-biotin-peroxidase complex staining system 
(Vector Laboratories, Burlingame, CA, USA) following the manufacturer’s instructions.  
RNA extraction and quantitative real-time PCR 
Skin biopsies were snap-frozen in liquid nitrogen and homogenized using a Mikro-
Dismembrator U (Braun Biotech, Göttingen, Germany) prior to RNA extraction. Total RNA 
containing the miRNA fraction was extracted from tissues and cells using Trizol (Life 
Technologies, Carlsbad, CA, USA) or the miRNeasy Mini kit (Qiagen, Hilden, Germany).  
Quantification of single miRNAs was performed using TaqMan Real-Time PCR (Life 
Technologies) according to manufacturer’s protocols and normalized towards small nucleolar 
RNAs U48 RNA (human) or snoRNA251 (murine) using ΔCt calculation. To quantify 
mRNAs, total RNA was reverse transcribed using the RevertAid First Strand cDNA 
Synthesis Kit (Fermentas, Pittsburgh, PA, USA). IL-8 and TNF-α were quantified using 
specific primers and probes (IL-8 fwd: CCACACTGCGCCAACA; rev:  
GCATCTTCACTGATTCTTGGAT; probe:  CTGGGTGCAGAGGGTTGTGG; TNF-α fwd:  
TCTTCTCGAACCCCGAGTGA; rev:  CCTCTGATGGCACCACCAG; probe:  
TAGCCCATGTTGTAGCAAACCCTCAAGCT). Other mRNAs and pri-miRs were 
quantified by TaqMan gene expression assays (Life Technologies); Gene expression was 
normalized based on 18S RNA (18S fwd: CGGCTACCACATCCAAGGAA; rev: 
GCTGGAATTACCGCGGCT, probe: TGCTGGCACCAGACTTGCCCTC). 
Gene expression profiling  
MiRNA profiling was performed using the miRNA Taqman Low Density Array card A and 
B (v3.0) according to manufacturer’s instructions (Life Technologies). Gene expression 
profiling was performed using the Affymetrix GeneTitan ST1.2 platform. Array data were 
analyzed using significance analysis of microarrays (SAM).  
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Cell culture 
Normal human adult epidermal keratinocytes were purchased from Life Technologies and 
cultured in EpiLife serum-free medium including human keratinocyte growth supplement 
(HKGS) at a final Ca2+ concentration of 0.06 mM and 100 U/ml penicillin/streptomycin at 
37°C in 5% CO2. In order to avoid disturbance by the presence of hydrocortisone, HKGS was 
removed one day before treatment or transfection for most experiments.  
For stimulation experiments, keratinocytes were treated with the TLR ligands zymosan (100 
µg/ml), flagellin (10 ng/ml), poly(I:C) (30 ng/ml) or Pam3CSK4 (50 µg/ml) (Invivogen, 
Toulouse, France), or the cytokines IL-1β, IL-36α, IL-36β, IL-36γ (10 ng/ml), TNF-α (50 
ng/ml) (Immunotools, Friesoythe, Germany) or TGF-β1 (3 ng/ml) (R&D systems). For 
inhibiting signaling pathways, keratinocytes were treated with BAY-11-7082 (an NF-κB 
inhibitor), SB203580 (a p38 inhibitor), UO126 (a MEK1/2 inhibitor) (Merck, Darmstadt, 
Germany) or SP600125 (a JNK inhibitor) (SantaCruz Biotechnology, Santa Cruz, CA, USA) 
at 10 µM or Wortmannin (a PI3K inhibitor) (Merck, Darmstadt, Germany) at 1 µM 
concentration. After one hour, medium, zymosan or IL-36α was added and cells were 
harvested 24 hours later. For functional studies, third passage keratinocytes at 50-60% 
confluence were transfected using Lipofectamine 2000 (Life Technologies) with pre-miR-
146a precursor or negative control #1 (1 nM; Life Technologies); miRCURY LNA 
microRNA Power inhibitor for hsa-miR-146a or negative control A (50 nM; Exiqon); 
miRIDIAN miR-31 hairpin inhibitor or microRNA hairpin inhibitor negative control #1 (10 
nM; ThermoFisher Scientific, Waltham, MA, USA); silencer select siRNA for TLR2, TLR3, 
TLR5 (10 nM), IRAK1, TRAF6, MYD88, STK40 (30 nM) or siRNA negative control #1 
(Life Technologies); siRNA for IRAK1 or siRNA negative control (160 nM; Life 
Technologies).  
Three dimensional epidermal equivalents  
Three-dimensional epidermal equivalents were obtained from MatTek (Ashland, MA, USA) 
and cultured according to manufacturer’s instructions at the air-liquid interphase in 
hydrocortisone-free medium. IL-1β, IL-17A, IL-22, IL-36α, IL-36β, IL-36γ, TGF-β1, TNF-α 
or IFN-γ (Immunotools) was added to the culture medium at 20 ng/ml for 72 hours. Parts of 
the tissue were FFPE sectioned and hematoxilin / eosin stained. The remaining tissue was 
snap-frozen in liquid nitrogen and subjected to RNA extraction.  
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Endothelial cell activation 
Human umbilical vein endothelial cells (HUVECs) were freshly isolated and maintained in 
Medium 199 (Life Technologies) containing 20% fetal calf serum, 28 μg/ml gentamycin, 2.5 
μg/ml amphotericin B, 1 ng/ml epidermal growth factor, and 1 μg/ml hydrocortisone (Sigma-
Aldrich). Alternatively, HUVECs were obtained from Life Technologies and cultured in 
Medium 200 containing low serum growth supplement (LSGS). HUVECs were treated with 
keratinocyte culture medium for four hours and then harvested.  
Chemotaxis assays 
Primary human leukocytes and neutrophils were isolated from 0.2% EDTA anticoagulated 
whole blood collected by venipuncture from healthy donors. Erythrocytes were removed 
using dextran sedimentation (2:1 mixture of blood:6% dextran / 0.9% NaCl), followed by 
hypotonic lysis using ddH2O. To isolate neutrophils, the purified leukocytes were layered 
over Ficoll-Paque (GE Healthcare, Little Chalfont, UK) and recovered from the pellet after 
centrifugation. The leukocytes or neutrophils were suspended in EpiLife serum-free 
keratinocyte growth medium, and 6×105 cells were added to the inner chamber of a 3 µm 
PET membrane cell culture insert (BD Falcon, Erembodegem, Belgium). The outer chamber 
contained culture medium from keratinocytes. After incubation for 1.5 (neutrophils) or 3 
hours (leukocytes) at 37°C in 5% CO2, the migrated cells in the outer chamber were 
quantified by CyQUANT GR dye (Life technologies) staining, or by flow cytometry, 
normalizing the culture medium volume by addition of CountBright counting beads (Life 
Technologies). 
Luciferase reporter assays 
Renilla luciferase reporter plasmids were obtained from SwitchGear Genomics (Carlsbad, 
CA, USA). The plasmids contained synthetic sequence repeats that are fully complementary 
to miR-31 (miR-31 sensor) or the 3'-UTR of the STK40 gene cloned downstream of the 
reporter gene. Mutations were generated at the predicted target site of the STK40 3'-UTR 
using the QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) 
according to the manufacturer’s instructions. The NF-κB reporter plasmid pGL4.32 
containing five copies of an NF-κB response element that drives transcription of the 
luciferase reporter gene luc2P was obtained from Promega (Madison, WI, USA). Human 
primary keratinocytes were co-transfected with the luciferase reporters (25 ng/ml) together 
with 10 nM anti-miR-31 or anti-miR-Ctrl using Fugene HD (Promega). For functional studies 
on miR-146a, pGL4.32 (400 ng/ml) was co-transfected into keratinocytes with a renilla 
control plasmid (20 ng/ml) and pre-miR-146a, pre-miR-Ctrl (1 nM), anti-miR-146a or anti-
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miR-Ctrl (50 nM) using Fugene HD. Luciferase activity was analyzed 24 hours post 
transfection using LightSwitch Luciferase Assay reagent (SwitchGear) or Dual-Luciferase 
Reporter Assay System (Promega).  
Protein detection 
Cell culture supernatant from keratinocytes was collected and stored at -80°C. ELISA 
measurement of the protein levels of IL-8, TNF-α (Biolegend, San Diego, CA, USA), CCL20 
(Boster Immunoleader, Fremont, CA, USA), CXCL1 and CXCL5 (R&D Systems, 
Minneapolis, MN, USA) was performed following the manufacturer’s instructions. 
Keratinocyte lysates were analyzed for protein expression by Western blotting with anti-
human IRAK1 (1:1000) or anti-human TRAF6 (1:500) antibodies (Cell signaling, Danvers, 
MA, USA). Actin expression was visualized using HRP-coupled anti-human Actin antibody 
(1:20000; Sigma-Aldrich).  
Statistics and data analysis  
Statistical significance was determined by Mann-Whitney U test or two-sided Student’s t-test. 
Data is presented as average ± standard deviation, unless indicated otherwise. P-values < 0.05 
were considered to be statistically significant. Correlation between the expression of different 
genes in the same samples was made using Pearson’s correlation test on log-transformed 
data. Microarray data were analyzed using the significance analysis of microarrays (SAM), a 
permutation-based method to estimate the false discovery rate in microarray analysis (Tusher 
et al., 2001). Categorization of genes according to GeneOntology terms was performed by the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang da et al., 
2009). Enrichment of NF-κB target genes among differentially expressed genes was analyzed 
by Gene Set Enrichment analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005). 
For the prediction of miRNA target genes the algorithms of TargetScan (Lewis et al., 2005), 
miRanda (John et al., 2004) and PicTar (Krek et al., 2005) were used.  
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4 RESULTS AND DISCUSSION  
4.1 IDENTIFICATION OF MICRORNAS INVOLVED IN THE INNATE IMMUNE 
FUNCTION OF KERATINOCYTES  
Antimicrobial defense is one of the key functions of the skin. Invading pathogens in the skin 
are recognized among others by TLRs expressed on keratinocytes, which induce an 
inflammatory response. The TLR-induced innate immune reactions of keratinocytes have 
been studied previously (Pivarcsi et al., 2003; Kollisch et al., 2005; Begon et al., 2007; Lebre 
et al., 2007). Nonetheless the role of miRNAs, which are regulatory elements in many 
immune reactions (O'Connell et al., 2012) has not been explored in this process. We therefore 
aimed to identify the miRNAs that are regulated in keratinocytes treated with TLR ligands. 
We chose ligands for TLR2, TLR5 and TLR3, since these TLRs are known to be expressed 
and functional in keratinocytes (Kollisch et al., 2005).  
We treated primary human keratinocytes with zymosan, a yeast cell wall component that acts 
as a ligand for TLR2, with flagellin, which is a bacterial protein stimulating TLR5, or with 
poly(I:C), a synthetic double-stranded RNA analogue that acts as a TLR3 ligand. The 
miRNA profile of the keratinocytes was determined six and 24 hours after the stimulation by 
Taqman Low Density Arrays. Relatively few miRNAs were de-regulated by the different 
TLR ligands six and 24 hours post stimulation (Figure 8; Paper I, Figure 1). Zymosan 
induced the expression of four and decreased the expression of three miRNAs, flagellin led to 
the increased expression of eight and the diminished expression of five miRNAs, while 
poly(I:C) induced 13 and decreased nine miRNAs in keratinocytes.  
MiR-146a was significantly induced by all tested TLR ligands, being by far the most up-
regulated miRNA in each category. Its induction was concentration-dependent (Paper I, 
Figure 2) and ligand-specific, as shown by siRNA-dependent knock-down of the regarding 
TLR (Paper I, Figure S2). Thus miR-146a appears to be a key miRNA in the general 
response of keratinocytes towards TLR stimulation and could have a common effect on TLR 
signaling. We further followed up the role of miR-146a specifically in TLR2 signaling in 
another study (chapter 4.2).  
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Figure 8: MicroRNA profile of 
TLR-ligand treated keratino-
cytes. Primary human keratino-
cytes were exposed to zymosan, 
flagellin or poly(I:C) in 
biological replicates for six or 
24 hours. Expression of 754 
miRNAs was measured using 
Taqman Low Density Arrays 
(TLDA). The heat map shows 
significantly differentially (FCH 
> 1.5; FDR < 0.1) expressed 
miRNAs.  
 
 
 
 
 
 
 
 
In contrast to miR-146a, other miRNAs were regulated by only one of the TLR ligands, 
hinting at a rather specific response of the keratinocytes towards different TLRs. For 
example, zymosan induced the expression of miR-203, a miRNA that has been implicated to 
regulate keratinocyte differentiation (Sonkoly et al., 2010), but also acts during inflammatory 
processes through targeting SOCS3 and IL-8 (Sonkoly et al., 2007; Wei et al., 2013). Another 
example is miR-135a, which was decreased by flagellin and which has been shown to 
regulate LPS-induced apoptosis in pulmonary epithelial cells (Zhao et al., 2014). MiR-155 is 
known to enhance the inflammatory response of immune cells and its overexpression has 
been linked to the development of autoimmune diseases, in humans as well as in mouse 
model systems (Seddiki et al., 2014). MiR-155 was induced exclusively by poly(I:C) in 
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keratinocytes, proposing that it could be involved in antiviral responses. Investigating the 
functional consequences of the TLR-induced regulation of the above mentioned and other 
miRNAs promises insights into the mechanism of the inflammatory response of 
keratinocytes.  
TLR signaling induces in general a strong NF-κB response (Kawai and Akira, 2006). This 
alone could not account for the vastly distinct miRNA profiles of keratinocytes stimulated 
with different TLR ligands. A specific response of the cell towards the different TLR stimuli 
and even to different ligands of the same receptor may require co-receptors and the 
combination of different intracellular adapter molecules, leading to the activation of 
additional transcription factors such as AP-1 and IRFs (Kondo et al., 2012). Since the 
expression of miRNAs depends on the activity of certain transcription factors, this might 
explain the distinct differences in the miRNA profile of the different TLR ligands.  
The difference of the miRNA profiles could have functional relevance and shape the response 
of keratinocytes towards different TLR stimuli. Since each miRNA regulates a specific set of 
target genes, changes in the miRNA profile may modulate the global transcriptome and thus 
affect the cellular behavior. MiRNAs regulated by TLR3 stimulation for example could 
prime keratinocytes to an antiviral response. To test this, the predicted target genes of the de-
regulated miRNAs could be clustered according to their function in a computational 
approach, potentially hinting towards a specific functional outcome. Functional studies of the 
de-regulated miRNAs will be able to verify such a hypothesis. In conclusion, the miRNAs 
found to be de-regulated in this study may contribute to the specificity of the innate immune 
response of keratinocytes towards different pathogens.  
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4.2 THE REGULATION OF MIR-146A BY TLR2 LIGANDS IN KERATINOCYTES  
4.2.1 The kinetics of miR-146a induction by TLR signaling   
Profiling of the miRNome of TLR-stimulated keratinocytes had identified miR-146a as the 
most consistently and strongest induced miRNAs after treatment with ligands for TLR2, 
TLR5 and TLR3 (chapter 4.1).  
In order to study the mechanisms underlying this phenotype, we investigated the regulation of 
miR-146a by TLR stimulation in detail, exemplified by the use of TLR2 ligands. We treated 
primary human keratinocytes with the TLR2 ligand zymosan and measured the expression of 
inflammatory mediators over time. As expected, the expression of IL-8, TNF-α and other 
inflammation genes was rapidly increased upon stimulation with TLR2 ligands, but their 
expression quickly returned back to base levels (Figure 9; Paper II, Figure 1c), which is in 
accordance with literature data (Larsen et al., 1989; Kawai et al., 2002; Pivarcsi et al., 2003). 
In contrast to that, miR-146a showed a distinct different kinetic profile. MiR-146a started to 
be induced by all treatments after approximately three hours, when the expression of the 
inflammatory mediators was already at its peak or started to decline, and it kept being up-
regulated for at least 96 hours, when IL-8 and other pro-inflammatory factors had long 
reached their basic expression level. This partly reciprocal kinetics led us to the question 
whether miR-146a could be involved in the down-regulation of inflammatory mediators and 
thus contribute to the resolution of inflammation in the skin (chapter 4.4).  
 
Figure 9: Expression kinetics of miR-146a of keratinocytes upon TLR2 stimulation. Keratinocytes were exposed 
to zymosan and expression of IL-8, TNF-α and miR-146a was determined over time using qRT-PCR. *p < 0.05; 
**p < 0.01; ***p < 0.001 
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4.2.2 Induction of miR-146a upon TLR2 stimulation is mediated through the 
NF-κB and MAPK pathways  
Next, we analyzed the pathways leading to the expression of miR-146a upon stimulation with 
TLR2 ligands. Silencing of TLR2 by siRNA knock-down completely abolished the induction 
of miR-146a by zymosan or Pam3CSK4, a synthetic TLR2 ligand (Paper II, Figure 1b), 
showing that miR-146a induction indeed was TLR2-dependent.  
The uttermost important downstream molecule in the inflammatory TLR signaling cascade is 
the transcription factor NF-κB, but also the MAPK pathways are known to partly transfer 
inflammatory signals within the cell (Kawasaki and Kawai, 2014). We therefore inhibited 
NF-κB and key components of the three major MAPK pathways (MEK1/2, JNK and p38) 
using chemical inhibitors. The induction of miR-146a by zymosan was majorly abolished 
upon blockade of NF-κB (Paper II, Figure 1d), indicating that the NF-κB pathway is indeed 
crucial for the up-regulation of miR-146a by TLR ligands. The strong dependence of miR-
146a expression on NF-κB signaling has previously also been shown in other cell types 
(Taganov et al., 2006; Bhaumik et al., 2008; Perry et al., 2009; Curtale et al., 2010), likely 
due to the three NF-κB binding sites in the miR-146a promoter (Taganov et al., 2006). 
Interestingly, also blockade of MEK1/2 and p38 diminished the induction of miR-146a by 
zymosan, while blockade of JNK had no effect on the zymosan-induced production of miR-
146a. Thus, the induction of miR-146a by TLR2 ligands depends on NF-κB, MEK1/2 and 
p38, demonstrating that besides the NF-κB pathway also the MAPK pathways are involved in 
the induction of miR-146a.  
Mature miRNAs are processed from their primary transcripts, the respective pri-miR, which 
are transcribed from the genome. To get an insight into the transcriptional regulation of the 
miR-146a gene, we studied also the expression of pri-miR-146a upon TLR2 stimulation. 
Treatment of keratinocytes with zymosan led to a quick but transient induction of pri-miR-
146a, following the kinetics of inflammatory mediators such as IL-8 (Paper II, Figure 1c). 
The discrepancy towards the slower and long-lasting induction of the mature miR-146a 
suggests that the continuous up-regulation of miR-146a upon TLR2 stimulation is not due to 
constant transcriptional activity of the miR-146a gene. This is also supported by the fact that 
NF-κB signaling plays a major role during the induction of miR-146a, which is known to act 
and to induce gene expression in the range of minutes (Napetschnig and Wu, 2013). Our data 
suggest that the long-term up-regulation of miR-146a in keratinocytes depends on the 
stability of the mature miR-146a. This is in line with reports showing that the half-life of 
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miRNAs can be up to several days long (Bail et al., 2010; Gantier et al., 2011). The long-term 
up-regulation of miR-146a is thus transcription-independent and does not rely on a constant 
stimulation of the cell. MiR-146a might therefore provide a regulatory mechanism, counter-
acting the acute pro-inflammatory reaction of keratinocytes upon an infection.  
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4.3 MIR-146A IN PSORIASIS  
Our and other groups have previously described the miRNA profile of psoriasis skin biopsies 
compared to healthy skin or non-lesional psoriasis skin (Sonkoly et al., 2007; Zibert et al., 
2010; Joyce et al., 2011). MiR-146a was one of the miRNAs that was consistently found to 
be up-regulated in psoriasis skin lesions. We aimed to characterize the regulation and 
function of miR-146a in psoriasis because its induction by TLR ligands in keratinocytes 
suggested a functional link towards the innate immune functions of keratinocytes, which are 
known to be disturbed in psoriasis skin.  
 
4.3.1 miR-146a is up-regulated in psoriasis keratinocytes  
The studies describing the psoriasis miRNA profile so far have worked with full-depth 
biopsies, mixing different cell populations from epidermis, dermis and even the underlying 
fat tissue. It is common to use whole tissue also for other organs to determine the miRNA 
expression profile in diseases (Pritchard et al., 2012), but this approach makes it impossible to 
predict which cell type is responsible for the observed phenotype. We therefore aimed to 
determine the cell type(s) responsible for the de-regulation of miR-146a in psoriasis skin. To 
that end we visualized the expression of miR-146a in sections of psoriasis skin lesions and 
healthy skin by in situ hybridization using specific probes. We found that miR-146a was 
strongly expressed by infiltrating immune cells and keratinocytes in the psoriasis lesions 
(Figure 10; Paper III, Figure 1c). It has previously been reported that activated immune cells 
(e.g. monocytes, mast cells, T lymphocytes, dendritic cells) express increased levels of miR-
146a (Taganov et al., 2006; Curtale et al., 2010; Jurkin et al., 2010; Rusca et al., 2012), 
making it likely that the highly activated immune cell infiltrate in the psoriasis skin lesions is 
a major source of the increased miR-146a expression in the full-depth biopsies. In addition to 
immune cells, also the keratinocytes in psoriasis lesions showed an increased expression of 
miR-146a compared to healthy skin, suggesting that they contribute to the up-regulation of 
miR-146a in psoriasis skin lesions.  
In order to confirm the role of keratinocytes for the miR-146a expression in psoriasis lesions 
in a more quantitative manner, we aimed to isolate keratinocytes from skin biopsies of 
psoriasis patients and healthy individuals. We chose an approach where the epidermis of 
freshly taken skin biopsies was separated from the underlying tissue by enzymatic digestion 
with dispase. The epidermis was then digested by trypsin into a single cell suspension and 
 44 
immune cells were depleted using CD45-antibody coupled magnetic beads. CD45 (also 
known as common leukocyte antigen; CLA) is expressed on all cells of the hematopoietic 
lineage and is thus well suited to mark immune cells (Altin and Sloan, 1997). The remaining 
epidermal CD45neg cells are supposed to consist mainly of keratinocytes and melanocytes. In 
Caucasians, melanocytes comprise to approximately 1 % of all epidermal cells (Brenner and 
Hearing, 2008), it is therefore unlikely that melanocytes would superimpose or skew the data 
of the keratinocyte population. We found that miR-146a was significantly increased in 
epidermal CD45neg cells of psoriasis lesions compared to epidermal CD45neg cells from 
healthy and also from non-lesional skin (Figure 10; Paper III, Figure 1b), demonstrating that 
indeed keratinocytes in psoriasis lesions express miR-146a at increased levels.  
Figure 10: MiR-146a is up-regulated in keratinocytes of psoriasis skin lesions. In situ hybridization of healthy 
skin and psoriasis lesions using a miR-146a-specific probe (left). Scale bar = 50 µm. Relative expression of miR-
146a measured by qRT-PCR in CD45neg epidermal cells from healthy skin, psoriasis non-lesional skin and 
psoriasis lesions (right). *** p < 0.001 
 
4.3.2 Induction of miR-146a by psoriasis-relevant cytokines   
Next, we aimed to understand what mechanisms could lead to the de-regulation of miR-146a 
in psoriasis keratinocytes. Since psoriasis lesions are an area of extensive inflammation, we 
looked at the effect of inflammatory cytokines. While conventional primary cell culture 
systems are well-established to study the function of keratinocytes in vitro, the interplay of 
keratinocytes in various stages of differentiation in the epidermal layers is not accounted for. 
In order to better mimic the processes in the skin, we employed in this experiment a three-
dimensional in vitro keratinocyte cell culture system. Grown at the interphase between air 
and culture medium, primary keratinocytes develop a three-dimensional structure that is 
analogue to the human epidermis (Andrei, 2006). We treated these three-dimensional 
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epidermal equivalents with a series of cytokines that have been implicated in the pathogenesis 
of psoriasis (IL-1β, IL-17, IL-22, IL-36, TNF-α, IFN-γ, TGF-β1). Treatment efficacy was 
evaluated by morphological changes of the three-dimensional structure of the models: IL-1β, 
and to a lesser extent IL-36α, IL-36β, IL-36γ and TNF-α decreased the epidermal thickness. 
In addition, IL-1β-treated epidermal equivalents showed extensive thickening of the stratum 
corneum. IL-22 and TGF-β1 induced epidermal thickening and hypogranulosis, while IFN-γ 
led to hypergranulosis. Moreover, inflammation markers such as IL-8, CCL20, β-defensin-2 
and CXCL9 were induced by the different cytokines, confirming the effective treatment 
(Paper III, Figure 2b-d). In this model system, miR-146a expression was strongly induced by 
IL-1β, IL-36α, IL-36β and IL-36γ, all members of the IL-1 cytokine family (Figure 11; 
Paper III, Figure 2a). In addition, also IL-17, IL-22 and TNF-α led to an induction of miR-
146a expression in three-dimensional epidermal equivalents.  
Figure 11: MiR-146a is regulated by 
psoriasis-associated cytokines. Three-
dimensional epidermal equivalents were 
treated with psoriasis-associated 
inflammatory cytokines for 72 hours. 
Expression of miR-146a was determined by 
qRT-PCR. * p < 0.05; ** p < 0.01; *** p < 
0.001 
 
 
Overall, these results demonstrate that miR-146a can be induced by various pro-inflammatory 
cytokines in keratinocytes, especially by members of the IL-1 cytokine family. This is in 
accordance with studies showing the regulation of miR-146a by IL-1β in keratinocytes 
(Rebane et al., 2014), but also in other cell types (Perry et al., 2009; Larner-Svensson et al., 
2010; Iyer et al., 2012; Li et al., 2012), hinting at a general mechanism of miR-146a induction 
rather than a cell type-specific regulation. The three IL-36 cytokines on the other hand are 
considered to act in a more tissue-specific manner. Their effect on miR-146a expression has 
not been explored previously. IL-1β, IL-36α, IL-36β and IL-36γ are all known to be present 
at high concentrations in psoriasis skin lesions (Debets et al., 2001; Blumberg et al., 2007; 
Johnston et al., 2011). Therefore it is very likely that IL-36 and IL-1β are responsible for the 
increased expression of miR-146a in psoriasis keratinocytes. Also IL-17, IL-22 and TNF-α 
are key cytokines in the pathogenesis of psoriasis. Their expression is increased in psoriasis 
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lesions (Lowes et al., 2013), thus potentially contributing to the observed phenotype. This 
hypothesis is supported by a report suggesting a correlation between the expression of miR-
146a and IL-17 in psoriasis lesions (Xia et al., 2012). Up-regulation of miR-146a in 
keratinocytes has also been reported in another chronic inflammatory skin disease, atopic 
dermatitis (Rebane et al., 2014), likely due to the high levels of IL-1β that are present in 
atopic dermatitis skin lesions (Krause et al., 2012). Thus, induction of miR-146a driven by 
IL-1 cytokines appears to be a general phenomenon of inflamed skin which can probably be 
observed in other inflammatory skin diseases.  
 
4.3.3 IL-36- and IL-1-dependent induction of miR-146a  
Our results suggest that IL-1 cytokines are potent inducers of miR-146a in keratinocytes. In 
order to get an insight into the detailed regulatory mechanisms, we treated primary human 
keratinocytes with IL-36α or IL-1β and measured the expression of inflammatory mediators 
such as IL-8 and TNF-α, as well as miR-146a over time. Comparable to the stimulation with 
TLR2 ligands, IL-8 and TNF-α were rapidly induced upon encounter with IL-1 cytokines, 
and their expression returned to base levels very quickly (Paper III, Figure 3a-b). MiR-146a 
expression on the other hand was induced by IL-36α and IL-1β after approximately three 
hours, and high levels of miR-146a were persistent for at least 96 hours. Thus, the kinetics of 
miR-146a induction by IL-1 cytokines, and the reciprocal decline of inflammation genes was 
similar to that of TLR2 ligand stimulation, hinting that the same intracellular signaling 
pathways are used.  
To decipher which signaling molecules are necessary for the induction of miR-146a by IL-36, 
we silenced MyD88, IRAK1 and TRAF6 by specific siRNA before treatment with IL-36α. 
Knock-down of MyD88 and IRAK1 indeed abolished the induction of miR-146a by IL-36α 
(Paper III, Figure 3d), suggesting that they are the primary signal transducers in direct 
connection to the IL-36 receptor, comparable to the TLR and IL-1 signaling cascade. In 
contrast, TRAF6 seemed not to be involved in the IL-36α-dependent miR-146a induction, 
thus other components of the inflammatory signaling cascade must be responsible for the 
further signal transduction and the transcription of the miR-146a gene.  
Further downstream in the TLR / IL-1 signaling cascade are the NF-κB and MAPK 
pathways. We tested the contribution of NF-κB, MEK1/2, JNK and p38 to the induction of 
miR-146a by IL-36α by using chemical inhibitors. MiR-146a was not induced by IL-36α 
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upon blockade of NF-κB which highlights the relevance of NF-κB in the induction of miR-
146a (Paper III, Figure 3e). Inhibition of JNK reduced the induction of miR-146a by IL-36α, 
while MEK1/2 and p38 had no effect, showing the additional contribution of MAPK 
pathways. Compared to the results from TLR2-stimulated keratinocytes, the induction of 
miR-146a seems to follow ligand-specific pathways. MiR-146a induction by zymosan 
depends on NF-κB, MEK1/2 and p38, while its induction by IL-36 depends on the NF-κB 
and JNK pathway. This is in accordance with data from epithelial alveolar cells, in which 
miR-146a was shown to be induced by IL-1β depending on the activity of NF-κB and JNK, 
but not on that of MEK1/2 or p38 (Perry et al., 2009). Taken together, our data revealed that 
besides the NF-κB pathway also the MAPK pathways are involved in the induction of miR-
146a, and that their involvement differs dependent on whether TLRs or IL-1 receptors are 
stimulated. These observations indicate that the regulation of miR-146a in keratinocytes by 
inflammatory stimuli is much more complex and fine-tuned than just an acute NF-κB 
response.  
Next, we tested the effect of IL-36ra on the induction of miR-146a. IL-36ra is a natural 
antagonist of the IL-36 cytokines that can effectively block the inflammatory activation of 
keratinocytes by IL-36α, IL-36β or IL-36γ (Debets et al., 2001; Towne et al., 2011). We 
found that pre-treatment of keratinocytes with IL-36ra could block the induction of miR-146a 
by IL-36α in a concentration-dependent manner (Paper III, Figure 3c), suggesting that the 
competition between IL-36 and IL-36ra in the epidermis also has implications for the 
expression level of miR-146a in keratinocytes.  
Overall, our data show that miR-146a can be induced in keratinocytes by TLR- or IL-1-
signaling via pathways that depend on the regarding receptors, MyD88, IRAK1 and NF-κB. 
Context-dependent, the different MAPK pathways also contribute to the induction of miR-
146a in keratinocytes, thus likely fine-tuning the response of keratinocytes to different 
stimuli. Most striking, the induction of miR-146a by both TLR stimulation and IL-1 cytokine 
signaling was very long-lasting, despite the normally quick and transient effects of the 
studied pro-inflammatory stimuli, proposing a regulatory function of miR-146a upon 
inflammatory stimulation.  
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4.4 THE FUNCTION OF MIR-146A IN KERATINOCYTES  
4.4.1 miR-146a suppresses the expression of inflammatory mediators  
Precise control of inflammation is necessary to sustain homeostasis, the failure to end 
inflammatory reactions after removal of the inducing pathogen is a hallmark of 
autoimmunity. Comparing the kinetics of the long-lasting up-regulation of miR-146a with the 
quick and transient expression of IL-8, TNF-α and other inflammation-related mediators 
raised the question whether miR-146a could be involved in the mechanisms leading to a 
down-regulation of inflammatory genes. To test this hypothesis, we overexpressed miR-146a 
in primary human keratinocytes by transfection with a synthetic precursor before treatment 
with zymosan. Indeed, the inflammation-induced expression and secretion of IL-8, TNF-α 
and CCL20 was markedly diminished by the overexpression of miR-146a (Paper II, Figure 
2a), suggesting that miR-146a can dampen the inflammatory response of keratinocytes that 
are stimulated by TLR ligands. The importance of miR-146a in this process became obvious 
upon inhibition of endogenous miR-146a by specific inhibitors. The already high levels of for 
example IL-8 after stimulation were increased to an even higher level when miR-146a was 
lacking (Paper II, Figure 2b). This shows the crucial importance of miR-146a in the 
limitation of the inflammatory response of keratinocytes. Therefore the up-regulation of miR-
146a upon stimulation by pathogens can be considered as a negative feedback mechanism, 
restricting the inflammatory reactions of the keratinocytes to the necessary minimum.  
The potential functionality of miR-146a as a negative feedback loop is also relevant in the 
inflammatory milieu of psoriasis lesions. We tested therefore the effect of miR-146a on the 
levels of inflammatory mediators induced by IL-1β and IL-36α. Overexpression of miR-146a 
suppressed the IL-36α- and IL-1β-induced expression of inflammation genes, while inhibition 
of endogenous miR-146a released the expression and secretion of IL-8 and other 
inflammatory mediators after IL-1β and IL-36α stimulation (Figure 12; Paper III, Figure 4). 
These results suggest that miR-146a could dampen the inflammation of psoriasis 
keratinocytes, proposing a model where the increased levels of miR-146a in psoriasis 
keratinocytes would contribute to an amelioration of the disease.  
Next, we investigated the role of miR-146a in unstimulated, resting keratinocytes. 
Overexpression of miR-146a suppressed the already low baseline production of inflammation 
genes (Figure 12; Paper II, Figure 3a; Paper III, Figure 4a-b). On the other hand, inhibition 
of the endogenous miR-146a in unstimulated keratinocytes led to a massive increase in the 
production of inflammatory mediators (Figure 12; Paper II, Figure 3b; Paper III, Figure 4c-
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d). This suggests that even the physiological low level of miR-146a in unstimulated 
keratinocytes fulfils a crucial function by suppressing an inflammatory reactions of the cell in 
the absence of any stimuli.  
Figure 12: MiR-146a suppresses the production of inflammatory mediators in keratinocytes. Keratinocytes were 
transfected with miR-146a precursor (pre-miR-146a) (left) or miR-146a inhibitor (anti-miR-146a) (right). 48 
hours later, IL-36α was added and the expression and secretion of IL-8 was measured six and 24 hours later by 
qRT-PCR and ELISA, respectively. *p < 0.05; **p < 0.01; ***p < 0.001   
 
4.4.2 miR-146a has a global impact on the transcriptome of keratinocytes  
In order to get a broader and more detailed view of the processes that are regulated by miR-
146a in keratinocytes, we performed a transcriptome profiling of keratinocytes 
overexpressing miR-146a. More than 400 genes were differentially expressed (Paper II, 
Table S1), many of them having immune-related functions. Several pro-inflammatory 
cytokines were down-regulated by miR-146a (e.g. IL-1β, IL-6, TNF-α). Many of these 
cytokines are relevant for the acute response of keratinocytes in inflammation. In chronic 
inflammation such as in psoriasis, these cytokines are overexpressed and targeted 
therapeutics against some of them have been shown to very effective (Lynch et al., 2014). 
This indicates that miR-146a modulates pathways that are relevant in the pathogenesis of 
psoriasis.  
The chemokines CXCL1, CXCL2 and IL-8 (CXCL8) were all repressed by miR-146a in 
keratinocytes. Considering their function as major attractors of neutrophils expressing their 
cognate receptors CXCR1 / CXCR2, this suggests that miR-146a largely represses the influx 
of the most acute immune mediators to the skin, which moreover are highly overrepresented 
and overactive in psoriasis lesions. IL-8 is also an important inducer of angiogenesis which is 
relevant for the pathogenesis of psoriasis (Heidenreich et al., 2009). Also other chemokines 
of key importance were suppressed by miR-146a, such as CXCL10 and CXCL11 (T cell 
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attracting), and CCL20 (attracting TH17 and other CCR6pos immune cells). Also CCL5, a 
chemokine attracting a mixture of immune cells was down-regulated upon overexpression of 
miR-146a. CCL5 has recently been shown to be a direct target of miR-146a in keratinocytes 
(Rebane et al., 2014), showing that the global transcriptomic changes by miR-146a are partly 
direct.  
Several antimicrobial peptides were repressed by miR-146a (α-defensin 5, β-defensin-113, β-
defensin-2), thus inhibiting one of the most powerful effector tools of keratinocytes in the 
antimicrobial defense. Of note, β-defensin-2 is one of the most up-regulated genes found in 
psoriasis skin lesions (Li et al., 2014a) and increased genomic copy numbers of β-defensin 
genes have been associated to psoriasis (Hollox et al., 2008). Also many other genes with 
crucial functions in immunity were suppressed by miR-146a, among them HLA genes, which 
are involved in the presentation of antigens towards immune cells (Howell et al., 2010; 
Dunphy and Gardiner, 2011), and signaling molecules which participate in the transduction 
of inflammatory signals within the cell (Hanada and Yoshimura, 2002). Altogether, these 
data show the overwhelming effect of miR-146a on the immune function of keratinocytes.  
Accordingly, categorization of the differentially expressed genes by GeneOntology categories 
revealed a high enrichment of categories such as “Immune response”, “Inflammatory 
response”, “Chemotaxis” or “Defense response” (Paper II, Figure 4a-c), confirming that 
miR-146a has a global impact on the immune function of keratinocytes.  
 
4.4.3 miR-146a regulates the NF-κB pathway  
Gene Set enrichment analysis (GSEA) showed that genes that are annotated as NF-κB targets 
were significantly enriched among the genes regulated by miR-146a (Paper II, Figure 4e), 
hinting at a connection between miR-146a expression and NF-κB activity. In order to verify 
this hypothesis, we transfected an NF-κB luciferase reporter plasmid into keratinocytes 
overexpressing or inhibited for miR-146a, thus measuring the activity of NF-κB. Indeed, 
miR-146a significantly suppressed the activity of NF-κB in zymosan-stimulated 
keratinocytes (Paper II, Figure 4f). These results confirm that the global repression of 
inflammatory genes in keratinocytes by miR-146a is likely due to a decreased activity of the 
NF-κB transcription factor.  
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4.4.4 miR-146a targets IRAK1 and TRAF6 
MiRNAs regulate gene expression by direct binding to the mRNA of its target genes, leading 
to transcriptional silencing. Several of the genes being down-regulated upon overexpression 
of miR-146a were predicted to be direct targets of miR-146a (Paper II, Table S1). Two of 
those, IRAK1 and TRAF6, are key signal transducers in the TLR and IL-1 signaling 
pathways (Takeda and Akira, 2004) and have previously been shown to be direct targets of 
miR-146a in monocytes by luciferase reporter assays (Taganov et al., 2006). Nonetheless, 
miR-146a did not target IRAK1 or TRAF6 in lung alveolar epithelial cells, indicating a cell-
type specific regulation (Perry et al., 2008).  
In keratinocytes, overexpression of miR-146a led to a significant repression of IRAK1 and 
TRAF6, both at mRNA and protein level, while miR-146a inhibition increased their 
expression (Paper II, Figure 5a-b), confirming that IRAK1 and TRAF6 are targeted by miR-
146a in keratinocytes. Direct targeting of IRAK1, TRAF6 and probably many more genes by 
miR-146a may explain the functional effect of miR-146a as a negative feedback-loop on 
TLR/IL-1-induced inflammatory stimuli.  
To study the relevance of IRAK1 as a target of miR-146a in TLR-induced inflammatory 
processes, we inhibited miR-146a in keratinocytes before treatment with zymosan. As shown 
before, the induction of IL-8 by zymosan was significantly higher in keratinocytes inhibited 
for miR-146a. Interestingly, this increase was completely abolished upon simultaneous 
knock-down of IRAK1 by siRNA (Paper II, Figure 5c), thus rescuing the lack of miR-146a 
by silencing of IRAK1. Taken together, our data suggest that miR-146a acts through IRAK1 
when dampening the inflammatory response of TLR-induced keratinocytes.  
 
4.4.5 miR-146a modulates the communication of keratinocytes with the local 
environment  
The production of inflammatory cytokines, chemokines and antimicrobial peptides by 
stimulated keratinocytes aims to create an inflammatory environment in the skin by attracting 
and activating professional immune cells from the circulation (Figure 2). We therefore aimed 
to determine whether miR-146a expression in keratinocytes modulates the communication 
towards other cell types in the skin. To enter the skin, immune cells in the blood stream need 
to first attach towards cell adhesion molecules on the surface of endothelial cells of the blood 
vessels before they can penetrate into the tissue and follow chemotactic gradients towards the 
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site of inflammation (Nourshargh et al., 2010; Wong et al., 2010). The expression of cell 
adhesion molecules such as ICAM-1, VCAM-1 or E-Selectin on endothelial cells can be 
regulated by cytokines and chemokines that are secreted by keratinocytes (Pober and Cotran, 
1990). We therefore treated endothelial cells (HUVECs) with culture medium from 
keratinocytes overexpressing or inhibited for miR-146a. MiR-146a overexpression in 
keratinocytes had a profound suppressive effect on the expression of ICAM-1, VCAM-1 and 
E-Selectin on endothelial cells, while miR-146a inhibition increased their expression (Paper 
III, Figure 5b). This suggests that the adhesion of leukocytes towards the wall of blood 
vessels is indirectly influenced by miR-146a expression in keratinocytes.  
Many different types of immune cell are attracted into the skin during inflammation. 
Neutrophils belong to the first cells that reach the inflamed tissue, thus being in the front line 
of defense against invading pathogens (Wright et al., 2010). Neutrophils are attracted by 
chemokines secreted from keratinocytes (especially IL-8, CXCL1 and CXCL2) (Kobayashi, 
2008). We therefore investigated the effect of miR-146a modulation on the leukocyte-
attracting capacity of keratinocytes.  
 
 
Figure 13: MiR-146a suppresses the capacity of keratinocytes to attract neutrophils. Keratinocytes were 
transfected with miR-146a precursor / inhibitor or regarding controls for 48 hours. The keratinocyte 
supernatant was used to attract primary neutrophils in a Boyden chamber and counted using flow cytometry. 
Plots showing forward/sideward scatter and quantification of migrated neutrophils. *p < 0.05  
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To that end we attracted primary neutrophils in a Boyden chamber towards conditioned 
keratinocyte medium. Keratinocytes overexpressing miR-146a had a significantly decreased 
ability to attract neutrophils, while keratinocytes inhibited for miR-146a attracted 
substantially more neutrophils (Figure 13; Paper II, Figure 4g; Paper III, Figure 5c-d). 
These data suggest that miR-146a influences the communication of keratinocytes with 
endothelial cells and immune cells, after all leading to a repression of the influx of immune 
cells into the skin.  
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4.5 MIR-146A – A GATEKEEPER OF IMMUNITY IN SKIN   
In summary, our data highlight the role of miR-146a as a novel player in innate immunity in 
the skin: MiR-146a is strongly induced in keratinocytes by different TLR signaling pathways. 
This suggests that encounter of keratinocytes with any class of pathogens would induce the 
expression of miR-146a, acting as a key player in the immune response of keratinocytes. 
MiR-146a has a massive impact on the gene expression profile and production of 
inflammatory mediators by keratinocytes which in turn modulates the infiltration of immune 
cells into the skin, thus dampening inflammation of the skin. Our results suggest that the 
induction of miR-146a in keratinocytes may play a role in the restoration of tissue 
homeostasis after an infection.  
On the other hand, we have shown that the baseline expression of miR-146a is crucial to 
prevent autoinflammation. Balancing its precise expression level is therefore vital to sustain 
homeostasis in the skin. In the absence of pathogens, miR-146a may define a threshold for 
the activation of keratinocytes by external stimuli, thus preventing autoimmunity.  
The strictly pro-inflammatory role of TLR signaling has been questioned by studies showing 
that a TLR3-induced inflammatory reaction of keratinocytes can be inhibited by TLR2 
ligands derived from commensal bacteria, but not from pathogenic bacteria (Lai et al., 2009). 
This modulation of inflammation by commensal bacteria was also shown in vivo, suggesting 
that the skin microbiome has influence on the immune reactivity of the skin. In regard to 
miR-146a, it is therefore possible that the constant exposure of keratinocytes towards 
commensal bacteria could control the expression level of miR-146a in keratinocytes. Thus, 
the skin microbiome would modulate the threshold for the activation of keratinocytes by 
pathogenic microbes.  
MiR-146a has previously been shown to have an anti-inflammatory function also in other cell 
types such as monocytes (Taganov et al., 2006), PBMCs (Tang et al., 2009), dendritic cells 
(Jurkin et al., 2010), regulatory T cells (Lu et al., 2010), lung epithelial cells (Perry et al., 
2008), microglial cells (Rom et al., 2010), evidently being a global player in the anti-
inflammatory response. In accordance with this, miR-146a knock-out mice spontaneously 
develop a severe general autoimmune phenotype and are prone to excessive inflammation, 
although skin alterations have not been described (Boldin et al., 2011; Yang et al., 2012).  
In an inducible model of atopic dermatitis, miR-146a knock-out mice showed increased 
expression of inflammatory mediators in the skin and extended immune cell infiltration 
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(Rebane et al., 2014). This suggests that only upon an external trigger the functional 
relevance of miR-146a becomes apparent in the skin. Nonetheless, the precise role of 
keratinocytes in this model remains to be investigated, since the studied mouse model is miR-
146a deficient in all cells. It is therefore also possible that other cell types, especially immune 
cells, modulate the reaction in the skin.  
We have shown that miR-146a is significantly up-regulated in psoriasis skin lesions. MiR-
146a has also been shown to be up-regulated in other inflammatory diseases, such as 
rheumatoid arthritis (Nakasa et al., 2008; Stanczyk et al., 2008) and Sjögren’s syndrome 
(Pauley et al., 2011). Considering that miR-146a is induced in a variety of activated immune 
cells (Taganov et al., 2006; Curtale et al., 2010; Jurkin et al., 2010; Rusca et al., 2012), the 
observed phenotype in these diseases might at least partly be caused by the activated immune 
cells. Whether tissue-resident cells contribute to the overexpression of miR-146a remains to 
be investigated. Interestingly, in systemic lupus erythematosus, another autoimmune disorder, 
miR-146a was found to be significantly down-regulated (Tang et al., 2009). This highlights 
the complexity of the interlaced feedback mechanisms and their dysregulation in chronic 
inflammatory diseases.  
In psoriasis, we have shown that keratinocytes significantly overexpress miR-146a, and that 
miR-146a functions as a potent anti-inflammatory regulator of keratinocytes. Nonetheless, 
chronic skin inflammation is active despite the increased expression of miR-146a. Since 
psoriasis has a strong genetic component, it is possible that genetic alterations in psoriasis 
patients render miR-146a dysfunctional, which in combination with other factors could 
manifest in chronic inflammation. Genome-wide association studies for psoriasis did not find 
an association between the miR-146a gene locus and the risk of psoriasis (Nair et al., 2009; 
Ellinghaus et al., 2010; Genetic Analysis of Psoriasis et al., 2010). During the writing of this 
thesis, a genetic variant of the miR-146a gene (SNP rs2910164) has been found to be 
associated with a significantly increased risk to develop psoriasis in the Chinese population 
(Zhang et al., 2014). Functionally, this polymorphism led to a down-regulated miR-146a 
expression in keratinocytes and an increased proliferation rate. This suggests that a genetic 
variation can decrease miR-146a expression and thus contribute to the pathogenesis of 
psoriasis. Further studies need to determine whether this polymorphism affects also the anti-
inflammatory function of miR-146a in keratinocytes and thus modulates the immune 
response.  
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Another possibility is that miR-146a binding sites in the 3'-UTR of some of the important 
target genes are mutated in psoriasis patients, thus disturbing the miRNA-mRNA binding, or 
that novel binding sites are created in genes that are normally not targeted by miR-146a 
(Pivarcsi et al., 2014). Detailed studies analyzing the genome of psoriasis patients are needed 
to address this hypothesis, since such alterations in the individual genetic background could 
explain some of the psoriasis cases.  
Strikingly, not only mice with a genetic deletion of miR-146a, but also transgenic mice 
overexpressing miR-146a show signs of autoimmunity (Guo et al., 2013). Considering the 
anti-inflammatory effect of miR-146a in various cell types, it is surprising that also miR-146a 
overexpression causes an inflammatory phenotype in vivo. This seemingly paradoxical 
finding highlights gaps in our knowledge about the factors regulating the balance between 
homeostasis and autoimmunity. It indicates that even small changes in intricate regulatory 
networks may have unexpected effect on the functional outcome of a complex system. This 
finding proposes that the precise balance of miR-146a level is of major importance to sustain 
homeostasis. Interestingly, a similar concept has been proposed based on the computational 
modeling of multiplex cytokine-networks, showing that alterations in the cytokine profile can 
lead to the modification of feedback loop interactions between cells and cause a disease status 
(Valeyev et al., 2010). In regard to psoriasis, this means that increased levels of the anti-
inflammatory player miR-146a may not necessarily be beneficial in chronic inflammation. In 
our model systems we have studied the role of miR-146a in acute inflammatory responses, 
but it is not accounted for the chronicity of inflammation as in psoriasis. It is therefore also 
possible that the chronic overexpression of miR-146a in psoriasis keratinocytes has 
unexpected opposing effects on the inflammatory status of keratinocytes and actually 
worsens the disease.  
From a functional perspective, it is plausible that miR-146a cannot fully compensate for the 
deregulated immune response of psoriasis keratinocytes, acting as an anti-inflammatory 
counter-weight in a widely pro-inflammatory environment. After all, the increased expression 
of miR-146a in psoriasis keratinocytes may therefore still contribute to a decreased 
production of inflammatory mediators, thus ameliorating the disease.  
In conclusion, we have identified miR-146a as a novel regulatory element in keratinocyte 
immunity. We propose a model, where miR-146a is induced in keratinocytes by TLR ligands 
and pro-inflammatory cytokines such as IL-1β and IL-36 (Figure 14). Induction of miR-146a 
is long-lasting and leads to a negative feedback-loop by down-regulation of the IRAK1 / 
  57 
TRAF6 / NF-κB signaling cascade, thus dampening the TLR / IL-1-induced inflammatory 
response of keratinocytes. Under homeostatic conditions, miR-146a averts an immune 
reaction of keratinocytes in the absence of stimuli, thus preventing spontaneous 
autoinflammatory reactions in the skin. The up-regulation of miR-146a in psoriasis 
keratinocytes, likely due to high concentrations of IL-1 cytokines in psoriasis lesions, 
probably contributes to, but cannot completely suppress the deregulated immune reactions of 
psoriasis keratinocytes. Overall, miR-146a can thus be regarded as a gatekeeper of immunity 
in the skin.  
 
 
Figure 14: Schematic summary of the regulation  
and function of miR-146a in keratinocytes. 
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4.6 MIR-31 IN PSORIASIS  
MiR-31 was one of the miRNAs identified to be up-regulated in psoriasis skin biopsies 
(Sonkoly et al., 2007; Zibert et al., 2010; Joyce et al., 2011). Since skin is a complex tissue, 
we aimed to identify the cell type responsible for the up-regulation of miR-31 in psoriasis 
skin. In situ hybridization specific for miR-31 revealed that keratinocytes appear to be the 
source of miR-31 in the skin (Figure 15; Paper IV, Figure 1C). MiR-31 was only slightly 
expressed in the basal layers of healthy epidermis, but its expression was strongly increased 
in the basal and suprabasal layers of psoriasis lesions. This indication was supported by qRT-
PCR analysis of miR-31 expression in CD45neg epidermal cells, showing a drastic increase in 
miR-31 expression in psoriasis keratinocytes (Figure 15; Paper IV, Figure 1D).  
Figure 15: MiR-31 is up-regulated in keratinocytes of psoriasis skin lesions. In situ hybridization of healthy skin 
and psoriasis lesions using a miR-31-specific probe (left). Relative expression of miR-31 measured by qRT-PCR 
in CD45neg epidermal cells from healthy skin, psoriasis non-lesional skin and psoriasis lesions (right). ** p < 
0.01; *** p < 0.001  
 
In order to identify potential inducers of miR-31 expression in keratinoyctes, we investigated 
the effect of cytokines (TNF-α, IL-22, TGF-β1, IL-6, IL-20, IFN-γ, GM-CSF), growth factors 
(EGF, KGF) and keratinocyte differentiation-driving factors (high concentration calcium, 
TPA, cell confluence) on keratinocytes. Strikingly, miR-31 expression was only altered by 
one of the tested treatments: TGF-β1 (Paper IV, Figure 7A). TGF-β expression in the skin 
has been shown to correlate with the severity of psoriasis (Flisiak et al., 2002). Interestingly, 
a transgenic mouse model overexpressing TGF-β1 under a keratinocyte-specific promoter 
develops a psoriasis-like skin phenotype that can be ameliorated by clinical psoriasis 
therapies (etanercept) (Li et al., 2004; Han et al., 2010). We evaluated the expression of miR-
31 in the skin of these mice by qRT-PCR and in situ hybridization and found that 
keratinocyte-specific overexpression of TGF-β1 strongly increased miR-31 expression in 
vivo, while this effect was diminished by etanercept treatment (Paper IV, Figure 7B-C). 
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These results suggest that high levels of TGF-β in the psoriasis lesion might contribute to the 
observed up-regulation of miR-31 in psoriasis keratinocytes and that the expression of miR-
31 is tightly linked to disease activity in vivo.  
 
 
4.7 THE FUNCTION OF MIR-31 IN KERATINOCYTES  
4.7.1 miR-31 regulates inflammatory mediators  
We also aimed to determine the role of miR-31 in keratinocytes with a focus on its function 
in immunity. To that end we inhibited miR-31 in primary human keratinocytes by a specific 
inhibitor and measured the expression and secretion of a series of inflammatory mediators 
such as IL-8, CXCL1, CXCL5 and IL-1β. Inhibition of miR-31 significantly decreased the 
production of these immune mediators (Figure 16; Paper IV, Figure 2A-B), suggesting that 
miR-31 fulfils a pro-inflammatory role in keratinocytes.  
Figure 16: Inhibition of miR-31 suppresses the production of inflammatory mediators by keratinocytes. 
Keratinocytes were transfected with miR-31 inhibitors (anti-miR-31) or regarding controls (anti-miR-Ctrl) (left) 
and additionally treated with TNF-α (right). Expression and secretion of IL-8 (CXCL8) was analyzed by qRT-
PCR and ELISA, respectively. *p < 0.05; **p < 0.01; ***p < 0.001  
 
This was further supported by data from a genome-wide gene expression profiling of 
keratinocytes inhibited for miR-31, showing several immune-related genes to be differentially 
expressed (Paper IV, Table S1). The differentially expressed genes were significantly 
enriched for NF-κB target genes (Paper IV, Figure 4A), suggesting a functional connection 
between miR-31 and the NF-κB pathway. Decreased NF-κB activity in keratinocytes 
inhibited for miR-31 was indeed shown by luciferase reporter assays (Paper IV, Figure 4B), 
supporting that miR-31 has a pro-inflammatory function in keratinocytes.  
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Simulation of an inflammatory situation by addition of TNF-α led as expected to a strong 
induction of the inflammatory response genes (Figure 16; Paper IV, Figure 2C-D). This 
induction was diminished upon inhibition of endogenous miR-31, suggesting that 
keratinocytes need the presence of miR-31 in order to react with an appropriate inflammatory 
response towards a stimulus such as TNF-α.  
To test whether these changes in cytokine and chemokine production have an impact on the 
local environment, we studied the effect of conditioned keratinocyte medium on endothelial 
cells and leukocytes. HUVECs treated with culture medium from miR-31-inhibited 
keratinocytes expressed significantly less adhesion molecules (ICAM-1, VCAM-1, E-
Selectin) (Paper IV, Figure 3A). Moreover, TNF-α-stimulated keratinocytes inhibited for 
miR-31 attracted fewer leukocytes, as measured by quantification of migrated leukocytes 
(Paper IV, Figure 3B). Taken together, these results strongly suggest that miR-31 modulates 
the cytokine and chemokine profile of keratinocytes towards a more pro-inflammatory 
mixture which in turn leads to an increased influx of immune cells into the skin.   
 
4.7.2 miR-31 targets STK40  
To get a functional insight into the mechanisms leading to the pro-inflammatory effect of 
miR-31, we were searching for potential target genes. By comparing the list of genes up-
regulated by miR-31 inhibition (and thus potential targets) with in silico predictions of miR-
31 target genes, we found STK40 to be a promising candidate gene. STK40 is a 
serine/threonine kinase that negatively regulates NF-κB signaling induced by TNF-α (Huang 
et al., 2003). It appears to be essential for the maturation of lung epithelium (Yu et al., 2013). 
STK40 has previously been proposed as a potential target of miR-31 in ovarian cancer cell 
lines (Creighton et al., 2010), but a direct interaction was not confirmed. We therefore used a 
luciferase reporter plasmid containing the 3'-UTR of the STK40 gene and co-transfected it 
together with miR-31 inhibitor into keratinocytes. Inhibition of miR-31 released the 
luciferase activity, showing the negative effect of miR-31 on STK40 translation (Paper IV, 
Figure 5D). This release was completely abolished upon mutation of the two predicted 
binding sites for miR-31 in the STK40 3'-UTR, confirming the direct interaction of miR-31 
with the STK40 mRNA.  
In skin, STK40 was expressed by keratinocytes, mainly in the granular layers of the 
epidermis (Paper IV, Figure 5E). In healthy skin also a weak expression was detected in the 
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basal and spinous layers, while STK40 was completely absent in the basal and lower spinous 
layers in psoriasis lesions. In contrast, miR-31 was majorly expressed in the basal and 
suprabasal layers of the epidermis. This reciprocal expression of STK40 and miR-31 in vivo 
further supports that miR-31 directly targets STK40.  
Next, we aimed to assess the importance of STK40 in mediating the effects of miR-31 on 
inflammatory signaling. The decreased expression of inflammatory cytokines and 
chemokines by miR-31 inhibition could be rescued upon silencing of STK40 via siRNA 
(Paper IV, Figure 6B-C), suggesting that the pro-inflammatory function of miR-31 is, at least 
partly, accomplished through targeting of STK40.   
 
 
4.8 MIR-31 – A PRO-INFLAMMATORY MIRNA   
Our data suggest that expression of miR-31 promotes inflammation in keratinocytes. But the 
role of miR-31 in keratinocytes is not limited to a pro-inflammatory function. Our group has 
shown that miR-31 also promotes cell proliferation and migration in the context of skin 
wounding, thus contributing to re-epithelialization of the skin (Li et al., 2014b). This suggests 
that also in psoriasis, up-regulation of miR-31 may increase keratinocyte proliferation, 
potentially contributing to the hyper-proliferative phenotype observed in psoriasis lesions. 
Also multiple cancers display a major de-regulation of miR-31, leading to a change of cancer-
associated phenotypes, but its regulation and functional role appears to be largely cell-type 
dependent (Laurila and Kallioniemi, 2013). We have shown that in cutaneous squamous cell 
carcinoma, a malignant transformation of keratinocytes, miR-31 was up-regulated, inducing 
migration and thus possibly raising the metastatic potential of the tumor cells (Wang et al., 
2014). In accordance, keratinocyte-specific overexpression of miR-31 in mice increases their 
susceptibility for developing squamous cell carcinoma (Tseng et al., 2014), highlighting the 
significance of miR-31 in keratinocyte biology. The up-regulation of the oncogenic miR-31 
in keratinocytes of psoriasis lesions could therefore promote the development of squamous 
cell carcinoma. In line with this, epidemiological studies have shown that psoriasis patients 
have an increased risk to develop squamous cell carcinoma (Pouplard et al., 2013).  
In summary, our data highlight the importance of miR-31 in the regulation of inflammatory 
processes of keratinocytes. We have shown here that miR-31 is up-regulated in psoriasis 
keratinocytes, and that TGF-β1 can induce its expression. Functionally, inhibition of 
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endogenous miR-31 decreases the production of inflammatory mediators by keratinocytes 
and diminishes the attraction of leukocytes. STK40, a repressor of NF-κB signaling, is 
targeted directly by miR-31, which may at least partly explain the modulatory effect of miR-
31 on the inflammatory status of keratinocytes. Taken together, these results suggest a model 
where TGF-β in psoriasis lesions induce the expression of miR-31 in keratinocytes. MiR-31 
in turn suppresses STK40, thus releasing NF-κB signaling, inducing the production of 
inflammatory mediators and actively attracting immune cells to infiltrate into the skin. MiR-
31 can therefore be considered as a positive regulator of keratinocyte immunity, contributing 
to the highly pro-inflammatory environment in psoriasis lesions (Figure 17).  
 
 
Figure 17: Schematic summary of the regulation  
and function of miR-31 in keratinocytes. 
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5 CONCLUSION  
Protection against infections is crucial for any organism to survive. The recognition of and an 
appropriate inflammatory reaction against an invading pathogen is therefore vital. After 
clearance of an infection, the inflammation needs to be terminated, otherwise chronic 
inflammation and autoimmunity develop, which will weaken and eventually kill the 
organism. A wide variety of complex and often redundant regulatory networks balances the 
thin line between inflammation and homeostasis. The role of miRNAs in this equilibrium is 
only partly known and was the objective of investigation in this thesis.  
We show here that a number of miRNAs is regulated by the encounter of keratinocytes with 
TLR ligands, thus likely shaping the specific inflammatory response of the keratinocytes 
towards the pathogens. The miRNA expression profiles of keratinocytes treated with ligands 
for different TLRs has little overlap. Future studies will show whether these miRNAs might 
specify the response of keratinocytes towards different pathogens. Exempt from this notion is 
miR-146a, being strongly induced by all tested TLR ligands.  
MiR-146a itself can be induced in keratinocytes not only by various TLR ligands, but also by 
cytokines of the IL-1 family (IL-1β, IL-36). MiR-146a induction by inflammatory stimuli is 
surprisingly long-lasting, exceeding by far the acute inflammatory response of keratinocytes. 
Functionally, this up-regulation suppresses globally the production of cytokines, chemokines 
and other inflammatory mediators, at least partly by targeting IRAK1 and TRAF6 and thus 
repressing the NF-κB signaling pathway. MiR-146a decreases the ability of keratinocytes to 
activate endothelial cells and to attract immune cells, thus dampening the local inflammatory 
environment in the skin and reducing the infiltrate of immune cells into the skin. This 
immune-suppressive function of miR-146a is not only active as a negative feedback-loop in 
keratinocytes encountering TLR ligands or IL-1 cytokines, but also in resting, unstimulated 
keratinocytes, protecting from an undesired inflammatory reaction in the absence of a 
stimulus.  
MiR-146a is up-regulated in keratinocytes of psoriasis lesions, most likely by the presence of 
pro-inflammatory cytokines such as IL-36 and IL-1. We have demonstrated the capacity of 
miR-146a to suppress the inflammatory reactions of keratinocytes induced by IL-36 and IL-1. 
Nonetheless, despite the increased expression of miR-146a, keratinocytes in psoriasis skin 
lesions are still in a highly inflammatory state. This suggests that the anti-inflammatory effect 
of miR-146a is not sufficient to suppress chronic inflammation, or that parts of the regulatory 
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network around miR-146a are dysfunctional in psoriasis patients. The function of miR-146a 
in psoriasis therefore needs to be established in the future by in vivo models of psoriasis.  
We found that miR-31 is up-regulated in psoriasis keratinocytes, potentially by the presence 
of TGF-β, but it acts rather as an inducer of inflammation. In fact, keratinocytes need the 
activity of miR-31 to properly induce the NF-κB pathway, produce inflammatory mediators 
and attract leukocytes into the skin upon an inflammatory stimulus. Thus, miR-31 likely 
supports and sustains the pro-inflammatory status of keratinocytes in psoriasis lesions.  
Taken together, we have shown here two examples of miRNAs that have opposite functions 
in the immune response of keratinocytes, miR-146a which dampens inflammation and 
protects from an over-reactive immune response, and miR-31 which appears to be essential 
for keratinocytes to induce an inflammatory action. This emphasizes the complex regulatory 
feedback mechanisms within the cell that become unbalanced in chronic inflammation such 
as in psoriasis.  
To unveil these connections and to acknowledge the contribution of regulatory RNAs to the 
phenotype of chronic inflammation should be a major ambition for future studies in order to 
better understand the complex networks determining the balance between homeostasis and 
inflammation. These insights might lead to the development of novel therapeutic approaches 
targeting miRNAs, which emphasizes the clinical relevance of miRNA research. Moreover, 
the potential of miRNAs to serve as disease biomarkers and to predict therapy response may 
enable novel diagnostic applications.  
In conclusion, our studies highlight the importance of miRNAs in the immune response of 
keratinocytes and provide evidence for the complexity of the networks regulating 
inflammatory responses in the skin, both in health and disease.  
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